<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4723083</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0146256</article-id><article-id pub-id-type="publisher-id">PONE-D-15-30010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Genitourinary Tract Tumors</subject><subj-group><subject>Bladder Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Bladder Cancer</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Elements</subject><subj-group><subject>Platinum</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA repair</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA repair</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Biomolecular isolation</subject><subj-group><subject>RNA isolation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Biomolecular isolation</subject><subj-group><subject>RNA isolation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Cancer Therapy</subject><subj-group><subject>Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Chemotherapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Research and Development</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer</article-title><alt-title alt-title-type="running-head">Molecular Dissection of Induced Platinum Resistance</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Sisi</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="currentaff001"><sup>&#x000a4;a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hongyong</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scharadin</surname><given-names>Tiffany M.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zimmermann</surname><given-names>Maike</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Amy Wang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="currentaff002"><sup>&#x000a4;b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vinall</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="currentaff003"><sup>&#x000a4;c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Tzu-yin</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cimino</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chain</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vuyisich</surname><given-names>Momchilo</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gleasner</surname><given-names>Cheryl</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mcmurry</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malfatti</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Turteltaub</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Vere White</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Chong-xian</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Henderson</surname><given-names>Paul T.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, California, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Urology, University of California Davis, Sacramento, California, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Lawrence Livermore National Laboratory, Livermore, California, United States of America</addr-line></aff><aff id="aff004"><label>4</label><addr-line>VA Northern California Health Care System, Mather, California, United States of America</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Accelerated Medical Diagnostics Incorporated, Dublin, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ahmad</surname><given-names>Aamir</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Wayne State University School of Medicine, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Chong-xian Pan, Paul Henderson and George Cimino are shareholders of Accelerated Medical Diagnostics Incorporated, whose goal is to commercialize the use of drug-DNA adducts as biomarkers of chemotherapy resistance.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: PTH CXP RDW MM PC SW MM BH. Performed the experiments: SW AP BH RV HZ BH TL MV CG KM. Analyzed the data: SW HZ MZ AP TS GC MM CXP PTH MZ. Contributed reagents/materials/analysis tools: KT. Wrote the paper: SW CXP PTH TS MZ PC BH MM.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;a</label><p>Current address: Translational Medicine Research Institute, First Hospital of Jilin University, Changchun, Jilin, China</p></fn><fn fn-type="current-aff" id="currentaff002"><label>&#x000a4;b</label><p>Current address: Department of Psychology, University of California San Diego, La Jolla, California, United States of America</p></fn><fn fn-type="current-aff" id="currentaff003"><label>&#x000a4;c</label><p>Current address: California Northstate University College of Pharmacy, Rancho Cordova, California, United States of America</p></fn><corresp id="cor001">* E-mail: <email>paul.henderson@ucdmc.ucdavis.edu</email> (PTH); <email>cxpan@ucdavis.edu</email> (CXP)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>1</issue><elocation-id>e0146256</elocation-id><history><date date-type="received"><day>8</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2015</year></date></history><permissions><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0146256.pdf"/><abstract><p>We report herein the development, functional and molecular characterization of an isogenic, paired bladder cancer cell culture model system for studying platinum drug resistance. The 5637 human bladder cancer cell line was cultured over ten months with stepwise increases in oxaliplatin concentration to generate a drug resistant 5637R sub cell line. The MTT assay was used to measure the cytotoxicity of several bladder cancer drugs. Liquid scintillation counting allowed quantification of cellular drug uptake and efflux of radiolabeled oxaliplatin and carboplatin. The impact of intracellular drug inactivation was assessed by chemical modulation of glutathione levels. Oxaliplatin- and carboplatin-DNA adduct formation and repair was measured using accelerator mass spectrometry. Resistance factors including apoptosis, growth factor signaling and others were assessed with RNAseq of both cell lines and included confirmation of selected transcripts by RT-PCR. Oxaliplatin, carboplatin, cisplatin and gemcitabine were significantly less cytotoxic to 5637R cells compared to the 5637 cells. In contrast, doxorubicin, methotrexate and vinblastine had no cell line dependent difference in cytotoxicity. Upon exposure to therapeutically relevant doses of oxaliplatin, 5637R cells had lower drug-DNA adduct levels than 5637 cells. This difference was partially accounted for by pre-DNA damage mechanisms such as drug uptake and intracellular inactivation by glutathione, as well as faster oxaliplatin-DNA adduct repair. In contrast, both cell lines had no significant differences in carboplatin cell uptake, efflux and drug-DNA adduct formation and repair, suggesting distinct resistance mechanisms for these two closely related drugs. The functional studies were augmented by RNAseq analysis, which demonstrated a significant change in expression of 83 transcripts, including 50 known genes and 22 novel transcripts. Most of the transcripts were not previously associated with bladder cancer chemoresistance. This model system and the associated phenotypic and genotypic data has the potential to identify some novel details of resistance mechanisms of clinical importance to bladder cancer.</p></abstract><funding-group><funding-statement>AMS samples were analyzed at Lawrence Livermore National Laboratory under the auspices of the DOE contract DE-AC52-07NA27344 and supported by NIH/NCRR Resource for Biomedical Accelerator Mass Spectrometry P41 RR013461 and DOE LDRD grant 08-LW-100 (PTH and KT), and by the American Cancer Society Institutional Research Grant (CXP). This study was also supported by the VA Career Development Award-2 (CXP), an NCI Cancer Center Support Grant (RDW) a Cancer Clinical Investigator Team Leadership Award (CXP), and NIH awards HHSN261201200048C, HHSN261201200084C, R01CA155642 (PTH) and T32 CA108459-08 (TS). The authors gratefully acknowledge the Susan and Gerry Knapp Family Fund. This work was performed, in part, under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344. The work reported here does not represent the views or opinions of the Department of Veterans Affairs or the United States Government.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="18"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Any RNA seq data not presented in the paper are available online at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sra">http://www.ncbi.nlm.nih.gov/sra</ext-link>. RNA seq data have been assigned accession ID numbers SRR1820076 and SRR1820077 for the 5637 parental line; and SRR1820079 and SRR1820080 for the 5637R line (representing two independent experiments for each cell line).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Any RNA seq data not presented in the paper are available online at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sra">http://www.ncbi.nlm.nih.gov/sra</ext-link>. RNA seq data have been assigned accession ID numbers SRR1820076 and SRR1820077 for the 5637 parental line; and SRR1820079 and SRR1820080 for the 5637R line (representing two independent experiments for each cell line).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Platinum-based drugs are among the most frequently prescribed anticancer drugs, including cisplatin, carboplatin and oxaliplatin. Cisplatin has been used to treat a broad range of malignancies, such as testicular, lung, ovarian, bladder, head and neck carcinomas, and others. For all platinum-based agents, intrinsic or acquired drug resistance is the major reason for treatment failure (<xref ref-type="fig" rid="pone.0146256.g001">Fig 1A</xref>).</p><fig id="pone.0146256.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.g001</object-id><label>Fig 1</label><caption><title>DNA damage as the critical step in Pt-induced cell death.</title><p>(A) The major pathways of platinum (Pt) drug-induced cell death. After administration, cellular uptake and efflux determines the intracellular accumulation of Pt agents, which can be inactivated by the intracellular thiol-containing molecules. Eventually, Pt agents induce DNA damage, including drug-DNA adducts, which triggers cell cycle arrest and DNA repair. DNA adduct formation and repair determines the fate of cells, although other factors also play important roles, such as pro- and anti-apoptotic proteins. (B) Diagram showing the formation of carboplatin- and oxaliplatin-DNA adducts and the positions of the radiocarbon labels on each drug used for this study in order to enable quantification of drug-DNA adduct formation and repair by accelerator mass spectrometry.</p></caption><graphic xlink:href="pone.0146256.g001"/></fig><p>The anticancer action of platinum-based drugs is best known for cisplatin, which enters cells by both passive diffusion and active transport. For example, a copper transporter (CTR1) is known to contribute to cisplatin influx and modulates drug sensitivity in vitro [<xref rid="pone.0146256.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0146256.ref002" ref-type="bibr">2</xref>]. Two copper-efflux-transporting P-type adenosine triphosphates (ATP7A and ATP7B) also mediate intracellular cisplatin levels [<xref rid="pone.0146256.ref003" ref-type="bibr">3</xref>]. Other active transporters include the human organic cation transporter (hOCT) and the human multidrug and toxin extrusion (hMATE), which are found only in certain types of human cells, consistent with the observation that different tissues can vary in their platinum accumulation [<xref rid="pone.0146256.ref004" ref-type="bibr">4</xref>].</p><p>Once cisplatin is inside the cell, glutathione (GSH) and other thiols act as reducing agents to quench platinum toxicity. There is high correlation between intracellular GSH levels and resistance to cisplatin <italic>in vitro</italic> [<xref rid="pone.0146256.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0146256.ref007" ref-type="bibr">7</xref>]. Metallothionein proteins are a family of sulfhydryl-rich proteins that participate in heavy metal binding and detoxification and are increased in some cisplatin resistant bladder tumors [<xref rid="pone.0146256.ref008" ref-type="bibr">8</xref>]. Alterations of GSH levels and genes involved in GSH synthesis, as well as metalloproteins, have also been reported for oxaliplatin resistant cancer cell lines [<xref rid="pone.0146256.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0146256.ref010" ref-type="bibr">10</xref>].</p><p>Cisplatin and its aquated or hydroxylated metabolites act as bifunctional alkylating agents for DNA [<xref rid="pone.0146256.ref011" ref-type="bibr">11</xref>]. The resulting drug-DNA adducts block replication and cell division, and activate apoptosis [<xref rid="pone.0146256.ref002" ref-type="bibr">2</xref>]. Other species, such as cisplatin-DNA-protein crosslinks, are also likely to contribute to cisplatin toxicity [<xref rid="pone.0146256.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0146256.ref013" ref-type="bibr">13</xref>].</p><p>Cellular response to carboplatin (see structure in <xref ref-type="fig" rid="pone.0146256.g001">Fig 1B</xref>) is thought to be very similar to cisplatin exposure since both drugs form identical crosslink drug-DNA structures, except that carboplatin reacts with DNA more slowly than cisplatin [<xref rid="pone.0146256.ref014" ref-type="bibr">14</xref>]. Clinically, cisplatin and carboplatin have similar, but not identical efficacy, likely owing to differences in biochemistry and dosing regimens.</p><p>Oxaliplatin (<xref ref-type="fig" rid="pone.0146256.g001">Fig 1B</xref>) acts similarly to cisplatin by exerting its toxicity via drug-DNA adduct formation [<xref rid="pone.0146256.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0146256.ref017" ref-type="bibr">17</xref>]. Since oxaliplatin-DNA adducts have different chemical and biological properties from cisplatin-DNA adducts, it does not show full cross-resistance with cisplatin and is more efficient in, for instance, inhibiting DNA synthesis [<xref rid="pone.0146256.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0146256.ref020" ref-type="bibr">20</xref>]. Also, differences between cisplatin and oxaliplatin have been described for intracellular cascades induced by drug-DNA damage related to apoptosis and cell cycle arrest [<xref rid="pone.0146256.ref021" ref-type="bibr">21</xref>].</p><p>Nearly all platinum-based drug-DNA adducts are substrates for nucleotide excision repair (NER) [<xref rid="pone.0146256.ref002" ref-type="bibr">2</xref>]. Increased DNA repair rates have been documented to correlate with resistance to platinum drugs [<xref rid="pone.0146256.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0146256.ref022" ref-type="bibr">22</xref>&#x02013;<xref rid="pone.0146256.ref025" ref-type="bibr">25</xref>]. Platinum-DNA adducts are also substrates for the DNA mismatch repair system (MMR). MMR proteins have a much higher affinity for cisplatin- than for oxaliplatin-DNA adducts [<xref rid="pone.0146256.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0146256.ref027" ref-type="bibr">27</xref>]. It has been reported that a defective MMR activity results in an increased resistance of cell lines to cisplatin, but not to oxaliplatin [<xref rid="pone.0146256.ref019" ref-type="bibr">19</xref>], which may explain the relative efficacy of oxaliplatin in colorectal cancers that are often defective in MMR [<xref rid="pone.0146256.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0146256.ref029" ref-type="bibr">29</xref>].</p><p>Molecular pathway analysis has been highly successful in laboratory research for elucidating platinum-based drug resistance mechanisms. However, the resulting molecular signatures of drug resistance are rarely applicable to the clinic. One major reason for the huge gap between the laboratory research and clinical application is the highly complex nature of resistance mechanisms against cytotoxic drugs. At the cellular level, over 700 genes are involved in cellular response to platinum-based treatment [<xref rid="pone.0146256.ref030" ref-type="bibr">30</xref>].</p><p>This complexity motivated us to generate a nearly isogenic bladder cancer cell line for the purpose of extending the mechanistic analysis of platinum resistance to bladder cancer, for which platinum-based treatment is first line in Stage II and higher disease [<xref rid="pone.0146256.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0146256.ref032" ref-type="bibr">32</xref>]. We present in this paper a phenotypic and genotypic analysis of a parental bladder cancer cell line 5637 and a daughter cell line that was rendered resistant to platinum-based drugs by exposure to increasing concentrations of oxaliplatin over several months. We hypothesized that this pair of cell lines would exhibit differences in platinum drug accumulation, intracellular inactivation and drug-DNA formation and repair consistent with their sensitivity to each drug, and that gene expression analysis of these nearly isogenic cell lines will result in reasonable number of testable hypotheses that may be specific to bladder cancer. The cell lines were tested for sensitivity to several chemotherapy agents commonly used in the treatment of bladder cancer. The cell lines were also assessed in detail with respect to mechanistic differences in response to [<sup>14</sup>C]oxaliplatin and [<sup>14</sup>C]carboplatin. The <sup>14</sup>C tracer enabled determination of drug uptake and efflux by liquid scintillation counting (LSC) and drug-DNA adduct formation and repair by accelerator mass spectrometry (AMS). The cell lines were also analyzed for RNA transcript expression changes by RNAseq, which led to the identification of several known and some novel transcripts with respect to platinum-based drug resistance. The contribution of the genes represented by these transcripts to chemoresistance is largely unknown. Elucidation of these mechanistic details in subsequent work may ultimately help design personalized therapy to overcome chemoresistance and guide the development of novel therapeutic agents against bladder cancer.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Drugs</title><p>Oxaliplatin (5 mg/ml) was purchased from Sanofi-Aventis (Bridgewater, NJ, USA) and <sup>14</sup>C-labeled oxaliplatin ([<sup>14</sup>C]oxaliplatin) (specific activity of 58 mCi/mmol) and [<sup>14</sup>C]carboplatin (54 mCi/mmol) were purchased from Moravek Biochemicals. Mixtures of radiocarbon-labeled and non-labeled oxaliplatin or carboplatin (USP Pharmaceutical Grade) were used in order to minimize the usage of radiocarbon, and achieve the different specific activities required for this study. Drug solutions were prepared immediately prior to use. Other drugs were obtained from the UC Davis Cancer Center Pharmacy (USP Pharmaceutical Grade).</p></sec><sec id="sec004"><title>Cell lines</title><p>Human bladder cancer cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured with the recommended medium unless otherwise specified. To develop Pt-resistant sub-cell lines, 5637 (HTB-9) cells were cultured around the IC<sub>50</sub> concentrations of oxaliplatin intermittently with stepwise increase of oxaliplatin concentration. The oxaliplatin concentrations used ranged from 1.5 &#x003bc;M to 15 &#x003bc;M, which are physiologically relevant considering maximum plasma concentration in humans is approximately 10 &#x003bc;M [<xref rid="pone.0146256.ref033" ref-type="bibr">33</xref>]. After 10 months of culture, the resistant sub-cell line 5637R was developed. To confirm that 5637R originated from the parental 5637 cell line, samples of both cultures were sent to the ATCC Cell Line Authentication Service for cell verification per the ATCC protocol. Specifically, fifteen short tandem repeat (STR) loci plus the gender determining locus, amelogenin, were amplified using the commercially available PowerPlex<sup>&#x000ae;</sup> 16HS Kit from Promega. The cell line sample was processed using the ABI Prism<sup>&#x000ae;</sup> 3130 xl Genetic Analyzer. Data were analyzed using GeneMapper ID v 3.2 software (Applied Biosystems). Appropriate positive and negative controls were used throughout the test procedure.</p></sec><sec id="sec005"><title>MTT Assay to determine IC<sub>50</sub></title><p>The IC<sub>50</sub> values were determined after incubating cells for 72 hours with different concentrations of chemotherapeutic agents commonly used in treating bladder cancer, as previously described [<xref rid="pone.0146256.ref034" ref-type="bibr">34</xref>].</p></sec><sec id="sec006"><title>Oxaliplatin and carboplatin exposure and AMS analysis</title><p>Cells were seeded in 60 mm dishes at a density of 1 x 10<sup>6</sup> cells/dish and allowed to attach overnight in a 37&#x000b0;C humidified atmosphere containing 5% CO<sub>2</sub>. At hour 0, cells were dosed and incubated with 10 &#x003bc;M oxaliplatin supplemented with 5,000 dpm/ml of [<sup>14</sup>C]oxaliplatin or 100 &#x003bc;M carboplatin,supplemented with 50,000 dpm/mL [<sup>14</sup>C]carboplatin. The 24-hour incubation was used to mimic the <italic>in vivo</italic> oxaliplatin half-life (16.8 hours) in patients [<xref rid="pone.0146256.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0146256.ref036" ref-type="bibr">36</xref>]. The cells were then washed twice with phosphate-buffered solution (PBS) and maintained thereafter with drug-free culture media. DNA was harvested at time points over 24&#x02013;48 hours, as indicated, and purified with a Promega Wizard DNA purification kit. Ten micrograms of DNA per sample was converted to graphite and measured by AMS for <sup>14</sup>C quantification as previously described [<xref rid="pone.0146256.ref037" ref-type="bibr">37</xref>]. Triplicate sets of AMS experiments were performed and the data was plotted as time vs oxaliplatin-DNA adducts per 10<sup>8</sup> nt.</p></sec><sec id="sec007"><title>Determination of intracellular glutathione levels</title><p>Intracellular total glutathione (GSH) level was detected with a colorimetric GSH detection kit per manufacture&#x02019;s protocol (BioVision, Mountain View, CA). Approximately 10<sup>7</sup> cells were washed with ice-cold PBS, and lysed in GSH lysis buffer. After incubation on ice for 10 minutes, sulfosalicylic acid solution was added, and supernatant was collected for measurement of absorbance at 410 nm. GSH standard included in the kit was used to generate a standard curve for determining the sample GSH concentrations.</p></sec><sec id="sec008"><title>Statistics</title><p>We used quantitative summaries of the DNA damage, IC<sub>50</sub> and AUC (area under curve) values, separately by experiment, cell line and time (mean and standard deviation). Statistics were calculated with n = 3 for each cell line. ANOVA analysis of IC<sub>50</sub> and AUC data were based on a one-sided <italic>t</italic>-test. All tests were at an experiment-wise error rate of 0.05 and all analyses used SAS/STAT<sup>&#x000ae;</sup> or MedCalc<sup>&#x000ae;</sup> software.</p></sec><sec id="sec009"><title>RNAseq and qRT-PCR</title><p>Total RNA was isolated using Qiagen RNeasy mini kit. Co-purified genomic DNA was quantified using an 18S gene-specific quantitative PCR assay with human genomic DNA as the quantity standard. Since total RNA had high levels of genomic DNA contamination (predicted to account for 15&#x02013;68% of total reads), an additional DNase treatment step was added to the RNA purification protocol. This step reduced the DNA contamination to levels expected to produce &#x0003c;0.33% of total reads. rRNA was depleted from the samples using Epicentre's RiboZero H/M/R kit. Sequencing libraries were made from 40 ng of rRNA depleted RNA using Epicentre's ScriptSeq v2 RNA-Seq Library Preparation Kit. These samples were sequenced on 1/3 of a HiSeq PE 101 lane each at Los Alamos National Laboratory.</p><p>Raw sequencing data were processed by CASAVA 1.8 software (Illumina; San Diego, CA) and trimmed for quality (Q<sub>30</sub>, Phred scale). Analysis of RNA-Seq data was performed using a standard TopHat-Cufflinks workflow with human genome assembly (Feb. 2009, GRCh37/hg19) [<xref rid="pone.0146256.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0146256.ref039" ref-type="bibr">39</xref>]. The expression of a transcript was considered significantly regulated if FDR (p-value corrected for multiple testing) was less than 0.05.</p><p>For qRT-PCR, RNA was isolated from subconfluent dishes using the Qiagen RNeasy Mini Kit according to the manufacturer&#x02019;s instructions. cDNA was synthesized using the Thermo Scientific RevertAid RT kit. qRT-PCR was performed using the EconoTaq PLUS 2X master mix on a BioRad CFX96 Real-Time System instrument. The following primers were used: TSPAN7 (<monospace>ACCAAACCTGTGATAACCTGTCT, AGGGAGATATAGGTGCCCAGA</monospace>), AKR1C2 (<monospace>ATTGGAATGACATACTGCATCCT, GTTCAACCGTTTCTTACCTGTGG</monospace>), AKR1C1 (<monospace>CGCCTGCAGAGGTTCCTAAAA, ATCAATATGGCGGAAGCCAG</monospace>), CYR61 (<monospace>CCCGTTTTGGTAGATTCTGG, GCTGGAATGCAACTTCGG</monospace>), HTRA1 (<monospace>TCCCAACAGTTTGCGCCATAA, CCGGCACCTCTCGTTTAGAAA</monospace>), and AQP3 (<monospace>CCGTGACCTTTGCCATGTG, CGAAGTGCCAGATTGCATCATAA</monospace>). Any RNA seq data not presented in the paper is available online at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sra">http://www.ncbi.nlm.nih.gov/sra</ext-link>. Raw RNA seq data have been assigned accession ID numbers SRR1820076 and SRR1820077 for the 5637 parental line; and SRR1820079 and SRR1820080 for the 5637R line (representing two independent experiments for each cell line).</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><p>The generation of the 5637R cell line via induced drug resistance is described below, along with a variety of phenotypic and genotypic characterizations. Unless otherwise noted, comparisons between the two cell lines are presented in the order of 5637R versus 5637, respectively.</p><sec id="sec011"><title>Induction of Platinum Drug Resistance</title><p>The 5637R cell line was developed over 10 months of culture with a stepwise increase in the concentration of oxaliplatin in the media. The cytotoxicity of oxaliplatin to the 5637R line decreased by approximately 10-fold compared to the parental cell line (IC<sub>50</sub> of 26.1 &#x003bc;M versus 2.45 &#x003bc;M, p&#x0003c;0.0001, <xref ref-type="table" rid="pone.0146256.t001">Table 1</xref>). Unexpectedly, we were unable to develop a resistant 5637 derivative upon extended exposure to carboplatin. To ensure that 5637R originated from the parental 5637 cells, one aliquot of each cell line was sent to ATCC for determination of clonal fidelity. The 15 short tandem repeat (STR) loci plus amelogenin of the 5637 cell line used for this study were an exact match for the ATCC human cell line 5637 (HTB-9) in the ATCC database. The 5637 line had three alleles that 5637R lacked while all other alleles examined were the same for both cell lines, suggesting that 5637R is a derivative of 5637.</p><table-wrap id="pone.0146256.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.t001</object-id><label>Table 1</label><caption><title>Comparison of drug IC<sub>50</sub> values for 5637 and 5637R cells.</title></caption><alternatives><graphic id="pone.0146256.t001g" xlink:href="pone.0146256.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Cell lines</th><th align="center" rowspan="1" colspan="1">Oxaliplatin</th><th align="center" rowspan="1" colspan="1">Carboplatin</th><th align="center" rowspan="1" colspan="1">Cisplatin</th><th align="center" rowspan="1" colspan="1">Gemcitabine</th><th align="center" rowspan="1" colspan="1">Doxorubicin</th><th align="center" rowspan="1" colspan="1">Methotrexate</th><th align="center" rowspan="1" colspan="1">Vinblastine</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>5637 (&#x003bc;M)</bold></td><td align="char" char="." rowspan="1" colspan="1">2.45</td><td align="char" char="." rowspan="1" colspan="1">24.34</td><td align="char" char="." rowspan="1" colspan="1">0.59</td><td align="char" char="." rowspan="1" colspan="1">0.12</td><td align="char" char="." rowspan="1" colspan="1">0.27</td><td align="char" char="." rowspan="1" colspan="1">1.24</td><td align="char" char="." rowspan="1" colspan="1">0.000605</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>5637R (&#x003bc;M)</bold></td><td align="char" char="." rowspan="1" colspan="1">27.27</td><td align="char" char="." rowspan="1" colspan="1">72.18</td><td align="char" char="." rowspan="1" colspan="1">2.99</td><td align="char" char="." rowspan="1" colspan="1">1.44</td><td align="char" char="." rowspan="1" colspan="1">0.29</td><td align="char" char="." rowspan="1" colspan="1">2.01</td><td align="char" char="." rowspan="1" colspan="1">0.000595</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold><italic>P values</italic></bold></td><td align="char" char="." rowspan="1" colspan="1"><italic>&#x0003c;0</italic>.<italic>0001</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>&#x0003c;0</italic>.<italic>0001</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>0</italic>.<italic>049</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>0</italic>.<italic>0015</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>0</italic>.<italic>45</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>0</italic>.<italic>18</italic></td><td align="char" char="." rowspan="1" colspan="1"><italic>0</italic>.<italic>48</italic></td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec012"><title>Chemotherapy drug cytotoxicity</title><p>Cells were cultured with a range of concentrations of cisplatin, carboplatin, gemcitabine, doxorubicin, methotrexate and vinblastine for 72 hours followed by assessment of viability by the MTT assay (Mean values reported in <xref ref-type="table" rid="pone.0146256.t001">Table 1</xref>). These drugs were chosen because of their frequent use in the treatment of bladder cancer. The 5637R cell line was also more resistant to cisplatin, but to a much lesser extent than for oxaliplatin (IC<sub>50</sub> 2.99 &#x003bc;M versus 0.59 &#x003bc;M for 5637, p = 0.049), and to carboplatin (IC<sub>50</sub> = 72.18 &#x003bc;M versus 24.34 &#x003bc;M, p&#x0003c;0.0001). It was also more resistant to gemcitabine (IC<sub>50</sub> = 1.44 &#x003bc;M versus 0.12 &#x003bc;M, p = 0.0015), but both cell lines were equally sensitive to doxorubicin (IC<sub>50</sub> = 0.27 versus 0.29 &#x003bc;M, p = 0.45), methotrexate (IC<sub>50</sub> = 1.24 &#x003bc;M versus 2.01 &#x003bc;M, p = 0.18) and vinblastine (IC<sub>50</sub> = 0.61 nM versus 0.60 nM, p = 0.48).</p></sec><sec id="sec013"><title>Uptake and efflux</title><p>To determine drug uptake, cells were incubated with [<sup>14</sup>C]oxaliplatin or [<sup>14</sup>C]carboplatin, and sampled at various time points over 24 hours followed by isolation of cells and LSC analysis of intracellular drug accumulation. The 5637R line had a modest, but significantly lower peak intracellular oxaliplatin level at 24 hours (248.6 &#x000b1; 24.7 X 10<sup>6</sup> molecules per cell versus 303.7 &#x000b1; 14.2 X 10<sup>6</sup> molecules per cell for 5637 cells, p = 0.290) (<xref ref-type="fig" rid="pone.0146256.g002">Fig 2A</xref>). In contrast, both cell lines had similar levels of carboplatin uptake at 24 hours (1241 &#x000b1; 192 X 10<sup>6</sup> molecule per cell versus 1113 &#x000b1; 58 X 10<sup>6</sup> molecule per cell, p = 0.334), (<xref ref-type="fig" rid="pone.0146256.g002">Fig 2B</xref>).</p><fig id="pone.0146256.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.g002</object-id><label>Fig 2</label><caption><title>Drug uptake and efflux.</title><p>(A-B) Comparison of cell uptake and efflux. A. cell uptake of oxaliplatin. 5637R cells had decreased cell uptake. B: 5637 and 5637R had similar cell efflux rates. (C-D) Oxaliplatin and carboplatin cellular efflux differences between the two cell lines were not statistically significant.</p></caption><graphic xlink:href="pone.0146256.g002"/></fig><p>To determine drug efflux, cells were exposed to [<sup>14</sup>C]oxaliplatin or [<sup>14</sup>C]carboplatin for 4 hours, washed with PBS and cultured in drug-free medium for 24 hours. The culture medium was sampled by LSC at different time points for determination of the rate of efflux. There was no significant difference in oxaliplatin or carboplatin efflux between the two cell lines (the efflux at 24 hours was 1514 &#x000b1; 78 X 10<sup>6</sup> molecules versus 1693 &#x000b1; 244 X 10<sup>6</sup> molecules per cell for oxaliplatin, p = 0.293 (<xref ref-type="fig" rid="pone.0146256.g002">Fig 2C</xref>); and 542.3 &#x000b1; 44.5 X 10<sup>6</sup> molecules versus 482.5 &#x000b1; 35.9 X 10<sup>6</sup> molecules per cell for carboplatin, p = 0.14) (<xref ref-type="fig" rid="pone.0146256.g002">Fig 2D</xref>).</p></sec><sec id="sec014"><title>Intracellular inactivation</title><p>5637R cells had a significantly higher mean GSH concentration than 5637 cells (53.91 &#x000b1; 0.83 nmol/mg protein versus 46.93 &#x000b1; 1.20 nmol/mg protein. p = 0.003) (<xref ref-type="fig" rid="pone.0146256.g003">Fig 3A</xref>). To determine if the higher GSH concentration contributed to chemoresistance, both cell lines were cultured in the presence of buthionine sulphoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase, which is required for GSH biosynthesis [<xref rid="pone.0146256.ref040" ref-type="bibr">40</xref>]. BSO treatment decreased GSH in both cell lines in a dose-dependent manner (<xref ref-type="fig" rid="pone.0146256.g003">Fig 3B</xref>). Exposure of 5637R cells to 50 &#x003bc;M BSO followed by [<sup>14</sup>C]oxaliplatin exposure increased mean oxaliplatin-DNA adduct levels at 24 h from 285.4 &#x000b1;15.3 adducts per 10<sup>8</sup> nucleotides to 424.6 &#x000b1; 67.7 adducts per 10<sup>8</sup> nucleotide, but this was not statistically significant (p = 0.113). However, BSO treatment significantly decreased the oxaliplatin IC<sub>50</sub> from 26.08 &#x003bc;M for 5637R cells to 12.95 &#x003bc;M for BSO treatment (p = 0.002, <xref ref-type="fig" rid="pone.0146256.g003">Fig 3C</xref>). In contrast, BSO treatment had little effect on the sensitivity of 5637 cells to oxaliplatin (IC<sub>50</sub> of 2.45 &#x003bc;M untreated versus 2.36 &#x003bc;M with BSO exposure, data not shown. Unexpectedly, BSO exposure had no impact on the carboplatin IC<sub>50</sub> values for either cell line (data not shown).</p><fig id="pone.0146256.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.g003</object-id><label>Fig 3</label><caption><title>Drug inactivation by cellular glutathione.</title><p>(A) Comparison of carboplatin-DNA adduct formation between 5637 and 5637R. (B) Comparison and correlation of IC<sub>50</sub> values with carboplatin-adduct AUC, adduct levels four hours after dosing and DNA repair. (C) Comparison of cell uptake and efflux of carboplatin between 5637 and 5637R cells.</p></caption><graphic xlink:href="pone.0146256.g003"/></fig></sec><sec id="sec015"><title>Drug-DNA adduct formation and repair</title><p>Cells were cultured with [<sup>14</sup>C]oxaliplatin at 10 &#x003bc;M (the approximate peak human oxaliplatin plasma concentration during chemotherapy) for 24 hours, followed by washing and culture for an additional 24 hours [<xref rid="pone.0146256.ref033" ref-type="bibr">33</xref>]. This protocol crudely mimics the <italic>in vivo</italic> exposure of oxaliplatin (exponential decrease blood concentration over approximately a day). Cells were harvested at various time points over 48 hours for DNA extraction and accelerator mass spectrometry (AMS) analysis using methods previously reported [<xref rid="pone.0146256.ref041" ref-type="bibr">41</xref>]. Briefly, AMS works by breaking down the molecules in a sample into atoms that are then identified and quantified in a small particle accelerator [<xref rid="pone.0146256.ref042" ref-type="bibr">42</xref>]. If the sample is labeled with a rare isotope such as <sup>14</sup>C, the concentration of radiocarbon atoms in the particle beam can be used to calculate the concentration of drug in blood, tissue, cells and sub cellular components such as protein and DNA. AMS analysis typically requires the conversion of samples to graphite prior to analysis, which can be done using a high throughput parallel process. There was a time-dependent increase in oxaliplatin-DNA adduct levels during a 24-hour incubation, followed by a gradual decrease over the subsequent 24 hours owing to a combination of DNA repair and dilution of the signal by DNA synthesis. At all time points, the oxaliplatin-DNA adduct levels in 5637R cells were lower than the adduct levels in 5637 cells (<xref ref-type="fig" rid="pone.0146256.g004">Fig 4A</xref>). At 48 hours, 5637R cells had much lower DNA adducts than the parental 5637 cells (78 &#x000b1; 4 versus 505 &#x000b1; 63 adducts per 10<sup>8</sup> nucleotide, p&#x0003c;0.0001, <xref ref-type="table" rid="pone.0146256.t002">Table 2</xref>). The AUC of oxaliplatin-DNA adducts integrated over the 48 hours study time was significantly lower for 5637R cells (9,426 &#x000b1; 2457 adducts-hr per 10<sup>8</sup> nucleotides versus 27,720 &#x000b1; 2,985 adducts-hr per 10<sup>8</sup> nucleotides, p = 0.001, <xref ref-type="table" rid="pone.0146256.t002">Table 2</xref>).</p><fig id="pone.0146256.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.g004</object-id><label>Fig 4</label><caption><title>Oxaliplatin- and carboplatin-DNA adduct formation and repair.</title><p>Comparison of oxaliplatin- and carboplatin-DNA adduct formation between 5637 and 5637R cells. The chemoresistant 5637R cells had higher oxaliplatin-DNA adduct levels at all time points compared to more treatment sensitive 5637 cells.</p></caption><graphic xlink:href="pone.0146256.g004"/></fig><table-wrap id="pone.0146256.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.t002</object-id><label>Table 2</label><caption><title>Oxaliplatin-DNA adduct formation and repair.</title></caption><alternatives><graphic id="pone.0146256.t002g" xlink:href="pone.0146256.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Cell lines</th><th align="center" rowspan="1" colspan="1">48h</th><th align="center" rowspan="1" colspan="1">AUC<sub>0-48h</sub></th><th align="center" rowspan="1" colspan="1">DNA repair</th></tr><tr><th align="center" rowspan="1" colspan="1">(Adducts/10<sup>8</sup> nt)</th><th align="center" rowspan="1" colspan="1">(Adducts/10<sup>8</sup> nt&#x022c5;hour)</th><th align="center" rowspan="1" colspan="1">(Adducts/10<sup>8</sup> nt/hour)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>5637</bold></td><td align="center" rowspan="1" colspan="1">505&#x000b1;63</td><td align="center" rowspan="1" colspan="1">27,720 &#x000b1; 2,985</td><td align="center" rowspan="1" colspan="1">1.34 &#x000b1; 0.30</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>5637R</bold></td><td align="center" rowspan="1" colspan="1">78&#x000b1;4</td><td align="center" rowspan="1" colspan="1">9,426 &#x000b1; 2,457</td><td align="center" rowspan="1" colspan="1">3.48 &#x000b1; 0.15</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold><italic>P</italic></bold></td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>001</italic></td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>0012</italic></td><td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>0004</italic></td></tr></tbody></table></alternatives></table-wrap><p>For DNA repair studies, cells were exposed to [<sup>14</sup>C]oxaliplatin for 24h, washed and cultured further in oxaliplatin-free medium. The decrease of oxaliplatin-DNA adducts at several time points over the next 24 hours was used to calculate the drug-DNA adduct repair velocity. 5637R cells had a repair rate of 3.48 &#x000b1; 0.15 adducts per 10<sup>8</sup> nucleotides/hour and 1.34 &#x000b1; 0.30 adducts per 10<sup>8</sup> nucleotides-hour for 5637 cells (p = 0.0004, <xref ref-type="table" rid="pone.0146256.t002">Table 2</xref>).</p><p>The formation and repair of carboplatin-DNA adducts was similarly determined, but with shorter drug exposures (4 hour exposure followed by washing and a twenty hour incubation in drug-free media) in order to mimic the faster <italic>in vivo</italic> plasma half-life compared to oxaliplatin. Carboplatin-DNA adduct levels and drug-DNA repair rates were not significantly different between the two cell lines (AUCs of 4,527 &#x000b1; 895 versus 4,211 &#x000b1; 1,678 monoadduct-hr/10<sup>8</sup> nucleotides, p = 0.69, <xref ref-type="table" rid="pone.0146256.t002">Table 2</xref>; and drug-DNA repair rates of 6.30 &#x000b1; 3.10 versus 9.31 &#x000b1; 6.74 adducts/10<sup>8</sup> nucleotides/hour, p = 0.34 for 5637R and 5637 cells, respectively, (<xref ref-type="fig" rid="pone.0146256.g004">Fig 4B</xref>).</p></sec><sec id="sec016"><title>RNAseq analysis of 5637 and 5637R cells</title><p>Total RNA was isolated from subconfluent cells that were cultured in the absence of chemotherapy drugs, and used for analysis by RNA-seq. From duplicate independent experiments, there were a total of 83 RNAs with statistically significant expression changes, of which 50 were associated with known genes, one known microRNA and 22 novel transcripts (p &#x0003c; 0.05, <xref ref-type="supplementary-material" rid="pone.0146256.s001">S1 Fig</xref> and <xref ref-type="supplementary-material" rid="pone.0146256.s002">S1 Table</xref>). The remaining 10 transcripts represent genes that did not provide measurable expression in all replicates, but may still be of relevance to drug resistance. Four genes of known relevance to chemoresistance (TSPAN7, AKR1C2, AKR1C1, and CYR61) were shown to be significantly upregulated in the resistant cell line 5637R and two genes (HTRA1 and AQP3) were downregulated compared to the parental cell line 5637 (<xref ref-type="table" rid="pone.0146256.t003">Table 3</xref>). The RNA-seq results were further confirmed by qRT-PCR analysis of selected transcripts of RNA isolated from subconfluent cultures grown without drugs in duplicate (<xref ref-type="fig" rid="pone.0146256.g005">Fig 5</xref>).</p><table-wrap id="pone.0146256.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.t003</object-id><label>Table 3</label><caption><title>Chemoresistance-associated gene expression levels in 5637 and 5637R cells.</title></caption><alternatives><graphic id="pone.0146256.t003g" xlink:href="pone.0146256.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Gene Symbol</th><th align="center" rowspan="1" colspan="1">Description</th><th align="center" rowspan="1" colspan="1">5637 FPKM</th><th align="center" rowspan="1" colspan="1">5637R FPKM</th><th align="center" rowspan="1" colspan="1">Fold Change</th><th align="center" rowspan="1" colspan="1">P value</th><th align="center" rowspan="1" colspan="1">Q value</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1"><bold>Upregulated Genes</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">TSPAN7</td><td align="center" rowspan="1" colspan="1">tetraspanin 7</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">0.8041</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="char" char="." rowspan="1" colspan="1">0.00005</td><td align="char" char="." rowspan="1" colspan="1">0.0130415</td></tr><tr><td align="center" rowspan="1" colspan="1">AKR1C2</td><td align="center" rowspan="1" colspan="1">aldo-keto reductase family 1, member C2</td><td align="center" rowspan="1" colspan="1">3.22761</td><td align="char" char="." rowspan="1" colspan="1">42.6636</td><td align="char" char="." rowspan="1" colspan="1">13.21832563</td><td align="char" char="." rowspan="1" colspan="1">0.00005</td><td align="char" char="." rowspan="1" colspan="1">0.0130415</td></tr><tr><td align="center" rowspan="1" colspan="1">AKR1C1</td><td align="center" rowspan="1" colspan="1">aldo-keto reductase family 1, member C1</td><td align="center" rowspan="1" colspan="1">5.67159</td><td align="char" char="." rowspan="1" colspan="1">50.3706</td><td align="char" char="." rowspan="1" colspan="1">8.881213205</td><td align="char" char="." rowspan="1" colspan="1">0.00005</td><td align="char" char="." rowspan="1" colspan="1">0.0130415</td></tr><tr><td align="center" rowspan="1" colspan="1">CYR61</td><td align="center" rowspan="1" colspan="1">cysteine-rich, angiogenic inducer, 61</td><td align="center" rowspan="1" colspan="1">3.92516</td><td align="char" char="." rowspan="1" colspan="1">17.8771</td><td align="char" char="." rowspan="1" colspan="1">4.554489499</td><td align="char" char="." rowspan="1" colspan="1">0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.0216746</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Downregulated Genes</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">HTRA1</td><td align="center" rowspan="1" colspan="1">HtrA serine peptidase 1</td><td align="center" rowspan="1" colspan="1">23.9727</td><td align="char" char="." rowspan="1" colspan="1">2.47473</td><td align="char" char="." rowspan="1" colspan="1">-9.686996157</td><td align="char" char="." rowspan="1" colspan="1">0.00005</td><td align="char" char="." rowspan="1" colspan="1">0.0130415</td></tr><tr><td align="center" rowspan="1" colspan="1">AQP3</td><td align="center" rowspan="1" colspan="1">aquaporin 3</td><td align="center" rowspan="1" colspan="1">27.1631</td><td align="char" char="." rowspan="1" colspan="1">0.97132</td><td align="char" char="." rowspan="1" colspan="1">-27.96514022</td><td align="char" char="." rowspan="1" colspan="1">0.0001</td><td align="char" char="." rowspan="1" colspan="1">0.0216746</td></tr></tbody></table></alternatives></table-wrap><fig id="pone.0146256.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0146256.g005</object-id><label>Fig 5</label><caption><title>RNAseq and qRT-PCR show similar trends in gene expression levels for selected resistance-realated genes.</title><p>Four genes (TSPAN7, AKR1C2, AKR1C1, and CYR61) have increased levels in 5637R cells and two genes (HTRA1 and AQP3) have decreased levels in the resistant cells. (A) Fold changes in chemoresistance gene levels relative to the 5637 parental cells as determined by RNA-seq. (B) Fold change in chemoresistance gene transcript levels relative to the 5637 parental cells as determined by qRT-PCR.</p></caption><graphic xlink:href="pone.0146256.g005"/></fig></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>After ten months of cell culture under pressure from oxaliplatin exposure, the resulting resistant cell line retained a 5637 lineage as determined by STR analysis, which justified its designation as 5637R. Our results are comparable to other previous findings on parental and oxaliplatin resistant cancer cell lines cells [<xref rid="pone.0146256.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0146256.ref046" ref-type="bibr">46</xref>]. It is puzzling and surprising that carboplatin exposure of 5637 cells under similar experimental conditions did not produce a carboplatin resistant cell line, even though 5637R cells are significantly resistant to carboplatin. This is an unexpected result considering the nearly universal clinical onset of resistance in advanced cancers upon treatment with platinum-based regimen. The difficulty of inducing carboplatin resistance in 5637 cells may be due to the known poor cross resistance between oxaliplatin and carboplatin or cisplatin [<xref rid="pone.0146256.ref002" ref-type="bibr">2</xref>]. Oxaliplatin may induce a different set of mutation spectra compared to carboplatin, which has been reported in an <italic>Hprt</italic> gene mutation assay in CHO cells for a comparison between cisplatin and oxaliplatin [<xref rid="pone.0146256.ref047" ref-type="bibr">47</xref>]. Regardless of how they were generated, the resulting pair of cell lines represents a useful model system for induced drug resistance, especially considering their relatively few phenotypic and genotypic differences.</p><p>The 5637R/5637 pair was evaluated by the MTT assay for resistance to oxaliplatin and several drugs that are used in the treatment of bladder cancer. Oxaliplatin, carboplatin and gemcitabine were significantly less cytotoxic to 5637R cells. Doxorubicin, methotrexate and vinblastine were equally toxic to both cell lines. This result is not surprising considering acquired resistance to one drug often selects for one or more mechanistic pathways that have multiple drugs as substrates. In the clinic, response to first line platinum-based therapy is 40&#x02013;50% for muscle invasive bladder cancer, but once resistance ensues, subsequent treatments have just 10&#x02013;25% response rates [<xref rid="pone.0146256.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0146256.ref049" ref-type="bibr">49</xref>]. Although much additional work is needed, the MTT data from our model system indicate that it is feasible to have substantial cytotoxic response to subsequent chemotherapy after the onset of platinum drug resistance if the correct treatment is selected.</p><p>Perhaps the most common drug resistance mechanism is modulation of intracellular drug accumulation via changes in the rate of uptake and efflux [<xref rid="pone.0146256.ref042" ref-type="bibr">42</xref>]. 5637R and 5637 cell lines were characterized for drug uptake and efflux by measuring radiocarbon content in cells over time (uptake) and accumulation of radiocarbon in media (efflux) after exposure of cells to either [<sup>14</sup>C]oxaliplatin or [<sup>14</sup>C]carboplatin. There was significantly lower drug uptake in 5637R cells for oxaliplatin, but not for carboplatin (248.6 &#x000b1; 24.7 X 10<sup>6</sup> oxaliplatin molecules per cell versus 303.7 &#x000b1; 14.2 X 10<sup>6</sup> molecules per cell for 5637 cells, p = 0.029) (<xref ref-type="fig" rid="pone.0146256.g002">Fig 2A</xref>). Efflux was not significantly different for both cell lines regardless of whether they were exposed to oxaliplatin or carboplatin. These data support a contributing role for decreased drug uptake as a factor in the oxaliplatin resistance of 5637R cells. However, these observations do not explain increased carboplatin and gemcitabine resistance.</p><p>Since platinum drugs act as electrophiles to chemically bind to DNA, they are subject to intracellular inactivation by cellular antioxidants such as GSH. 5637R cells have significantly higher GSH levels than 5637 cells, indicating increased intracellular inactivation as a possible resistance mechanism. Exposure of 5637R to BSO reduced GSH, increased oxaliplatin-DNA adduct frequency and increased oxaliplatin cytotoxicity. In contract, BSO treatment had little effect on the sensitivity of 5637 cells to oxaliplatin. We previously observed these phenomena for carboplatin treatment in a variety of cancer cell lines [<xref rid="pone.0146256.ref050" ref-type="bibr">50</xref>]. It is difficult to understand why the 5637R cell line would have such a drastic difference in response to BSO treatment compared to 5637 cells. There is almost certainly a basal level of GSH required to maintain the net reducing environment needed for normal cell function, and GSH concentrations in excess of this level may be disproportionately able to contribute to drug resistance for electrophilic compounds such as the platinum drugs.</p><p>The level of drug-DNA adducts is the primary pharmacodynamic endpoint of platinum-based chemotherapy, and can vary substantially amongst different cell lines and tumors depending on a wide variety of known and unknown factors [<xref rid="pone.0146256.ref042" ref-type="bibr">42</xref>]. Under identical experimental conditions, 5637R cells exposed to oxaliplatin had significantly lower peak and overall oxaliplatin-DNA adducts over 48 hours. The repair rate of oxaliplatin-DNA adducts was also faster in 5637R cells, indicating DNA repair as an additional resistance mechanism. Carboplatin-DNA adduct formation and repair was not significantly different between the two cell lines, indicating yet additional carboplatin resistance mechanisms beyond those leading up to and including drug-DNA adduct formation and repair.</p><p>ERCC1 (Excision Repair Cross-Complementation Group 1) is a protein mainly involved in nucleotide excision repair, and increased ERCC1 expression is clinically associated with resistance to platinum [<xref rid="pone.0146256.ref051" ref-type="bibr">51</xref>, <xref rid="pone.0146256.ref052" ref-type="bibr">52</xref>]. We previously showed that inhibition of ERCC1 expression in lung cancer cells increased drug-DNA adduct formation and reduced repair of carboplatin-DNA monoadducts and partially reversed chemoresistance [<xref rid="pone.0146256.ref050" ref-type="bibr">50</xref>]. In this study, we saw no significant difference in transcripts related to ERCC1 in the RNAseq data, even though there was differential sensitivity to carboplatin. However, we did observe a significant difference in the rate of repair of oxaliplatin-DNA adducts, which could not be accounted for by differences in nucleotide excision repair capacity, at least not by mRNA expression. This example highlights the difficulty of finding generally applicable markers of platinum resistance.</p><p>In addition to functional analysis, we also performed RNA-seq followed by targeted qRT-PCR experiments with 5637 and 5637R cell lines cultured in the absence of drugs in order to simulate the patient between cycles of chemotherapy. Of the fifty transcripts that represent known genes, alterations in transcript levels were observed for six putative chemoresistance genes. Four genes, TSPAN7, AKR1C1, AKR1C2, and CYR61 have elevated expression levels in the resistant cell line compared to the parental cells. Tetraspanin 7 (TSPAN7) is a transmembrane protein involved in signal transduction. Increased levels of TSPAN7 in patients with acute lymphoblastic leukemia, chronic myeloid leukemia, or acute myeloid leukemia are associated with drug resistance [<xref rid="pone.0146256.ref053" ref-type="bibr">53</xref>]. AKR1C1 and AKR1C2 (aldo-ketose reductase family 1, members C1 and C2) or dihydrodiol dehydrogenase (DHH) are part of the progesterone metabolism pathway. Increased AKR1C1/2/3 levels are observed in cisplatin-resistant bladder cancer and colon cancer cell lines, leukemia cells continuously treated with daunorubicin, and in cisplatin-resistant ovarian cancers [<xref rid="pone.0146256.ref054" ref-type="bibr">54</xref>&#x02013;<xref rid="pone.0146256.ref057" ref-type="bibr">57</xref>]. Transfection of the AKR1 genes into cell lines enhances chemoresistance while siRNA knockdown or inhibition of the genes resensitizes the cells to drug treatment [<xref rid="pone.0146256.ref054" ref-type="bibr">54</xref>&#x02013;<xref rid="pone.0146256.ref056" ref-type="bibr">56</xref>]. A decreased level of ROS production was observed in the resistant cell lines treated with cisplatin. Since AKR1 is involved in cellular response to ROS, this result suggests that the resistance may be due to anti-oxidative effects [<xref rid="pone.0146256.ref055" ref-type="bibr">55</xref>, <xref rid="pone.0146256.ref056" ref-type="bibr">56</xref>]. Additionally, the pro-inflammatory pathway was shown to increase AKR1C1/2 levels in non-small cell lung cancer cells leading to cisplatin and doxorubicin resistance [<xref rid="pone.0146256.ref058" ref-type="bibr">58</xref>]. CYR61 is an extracellular matrix-associated protein that mediates cell proliferation, angiogenesis, and adhesion. Overexpression of CYR61 in breast cancer cells caused resistance to paclitaxel and PI3K pathway inhibitors, suggesting activation of the pro-survival PI3K pathway as a mechanism for resistance [<xref rid="pone.0146256.ref059" ref-type="bibr">59</xref>]. Similarly, overexpression of CYR61 in pancreatic cancer cells led to reduced gemcitabine sensitivity that could be reversed by siRNA knockdown of CYR61 [<xref rid="pone.0146256.ref060" ref-type="bibr">60</xref>]. Though further investigations are needed, these studies support the possibility of using TSPAN7, AKR1C1/2, and CYR61 as biomarkers for resistance and that knockdown or inhibition of these genes may prevent or reduce platinum chemoresistance in bladder cancer.</p><p>Conversely, we found two genes, HTRA1 and AQP3, with decreased expression in the resistant cell line compared to the parental cells. HTRA1 is a member of the serine protease family and a potential tumor suppressor that is downregulated in several cancer types. Low levels of HTRA1 attenuate cisplatin and paclitaxel toxicity in ovarian cancer cells treated with HTRA1 siRNA and developed cisplatin-resistant non-small cell lung cancer cell lines and xenografts [<xref rid="pone.0146256.ref061" ref-type="bibr">61</xref>, <xref rid="pone.0146256.ref062" ref-type="bibr">62</xref>]. Reexpression or overexpression of HTRA1 in the cell lines and xenografts improved drug sensitivity [<xref rid="pone.0146256.ref061" ref-type="bibr">61</xref>&#x02013;<xref rid="pone.0146256.ref063" ref-type="bibr">63</xref>]. Similar findings were observed in ovarian and gastric cancer patients where high HTRA1 levels correspond to the best response to cisplatin-based therapies [<xref rid="pone.0146256.ref061" ref-type="bibr">61</xref>, <xref rid="pone.0146256.ref064" ref-type="bibr">64</xref>]. Activation of the PI3K pathway is observed in low-HTRA1 NSCLC cells and inhibition of this pathway resensitizes cells to cisplatin treatment, suggesting one mechanism of resistance and potential treatment strategy [<xref rid="pone.0146256.ref062" ref-type="bibr">62</xref>]. Aquaporin 3, AQP3, is a small integral membrane protein involved in water transport across the plasma membrane. Similar to our findings, AQP3 levels were decreased in a cisplatin-resistant bladder cancer cell line compared to the parental cells [<xref rid="pone.0146256.ref065" ref-type="bibr">65</xref>]. Inhibition of AQP3 in bladder cancer cell lines or knockdown of AQP3 in breast and colon cancer cell lines decreases intracellular platinum concentration and attenuates the pro-apoptotic effects of nucleoside analog (5&#x02019; DFUR and gemcitabine) treatment, respectively [<xref rid="pone.0146256.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0146256.ref066" ref-type="bibr">66</xref>]. Low levels of HTRA1 and AQP3 are potential biomarkers for chemoresistance. Of course, increasing the levels of these proteins in tumors is a more difficult task than decreasing the levels of overexpressed or aberrantly activated genes. Understanding the mechanism of decreased expression could identify a potential means of reversing or reducing the chemoresistance, such as inhibition of the PI3K pathway in NSCLC cells with low HTRA1 expression. A few of the genes identified have been associated with alterations epithelial-mesenchymal transition (EMT) pathways, which have also been implicated in platinum chemoresistance in bladder cancer. These include NKX1-2, CHD8 and MFAP5, which may be potentially useful signatures of resistance [<xref rid="pone.0146256.ref067" ref-type="bibr">67</xref>&#x02013;<xref rid="pone.0146256.ref069" ref-type="bibr">69</xref>].</p><p>The importance of non-coding RNAs, particularly long noncoding RNAs (lncRNAs), in cancer development has been increasingly acknowledged [<xref rid="pone.0146256.ref070" ref-type="bibr">70</xref>]. Among the 22 novel transcripts showing significant differential expression, only one 158 bp sequence can be classified as putative small regulatory RNAs. Most range in size between 300 bp-7 kb, several are 11&#x02013;14 kb in length and a few are very large, from 38 kb up to 91 kb (see <xref ref-type="supplementary-material" rid="pone.0146256.s003">S2 Table</xref>). It is interesting that novel transcripts with non-zero fragments per kilobase of exon per million fragments mapped (FPKM) in both cell types are much longer than those with zero FPKM in one cell type. Additional experiments will be required to validate these transcripts and further explore their potential roles in bladder cancer development.</p></sec><sec sec-type="conclusions" id="sec018"><title>Conclusions</title><p>Resistance to chemotherapy is a highly complicated process. The cytotoxic nature of non-targeted cytotoxic drugs results in the alteration of the expression of hundreds of genes [<xref rid="pone.0146256.ref030" ref-type="bibr">30</xref>]. In order to address the issue of genetic complexity in a model system, we undertook a functional and molecular analysis of two closely related cancer cell lines as a model system of drug resistance in bladder cancer. We performed a phenotypic and genotypic assessment of the major mechanistic pathways involved in the acquired chemoresistance of the 5637R cell line. The goal was to simplify mechanistic studies in a novel bladder cancer model system, but also to lay the foundation to someday guide the selection of therapeutic agents to overcome resistance specifically in the bladder cancer setting.</p><p>The phenotypic analysis indicated that drug accumulation, intracellular inactivation, drug-DNA damage and repair all contributed to oxaliplatin resistance in 5637R cells, whereas the RNAseq data revealed a contribution to post-DNA damage pathways related to many cancer-relevant processes such as apoptosis, growth signaling and others. Interestingly, there was not a clear link between the transcript expression levels and the observed differential repair of drug-DNA adducts. Perhaps subtle gene expression level differences or other regulatory mechanisms are important in regulating DNA repair as part of acquired drug resistance. Taken together, these seemingly disparate functional and molecular data sets form a foundation for additional novel investigations into chemoresistance. Most of the genes identified in the RNAseq analysis are novel for bladder cancer, which provides an opportunity for new testable hypotheses to tie these novel resistance genes to the now canonical phenotypic resistance pathways.</p><p>In conclusion, we have developed a nearly isogenic pair of cell lines that can be used to study chemoresistance in bladder cancer. Functional and mRNA expression analysis elucidated the major resistance pathways demonstrating feasibility for use of this model system as a tool to study the influence of specific gene expression or mutation differences to improve our understanding of drug resistance with the goal of ultimately guiding the design of new chemotherapy diagnostics and treatments. Future work will focus on functional assessment of the candidate transcripts identified in this report and on assessment of transcript expression changes in these cell lines upon platinum drug exposure.</p></sec><sec sec-type="supplementary-material" id="sec019"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0146256.s001"><label>S1 Fig</label><caption><title>Differentially expressed transcripts for 5637 and 5637R cells.</title><p>(TIFF)</p></caption><media xlink:href="pone.0146256.s001.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0146256.s002"><label>S1 Table</label><caption><title>Differentially expressed known transcripts.</title><p>(PDF)</p></caption><media xlink:href="pone.0146256.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0146256.s003"><label>S2 Table</label><caption><title>Differentially expressed novel transcripts.</title><p>(TIFF)</p></caption><media xlink:href="pone.0146256.s003.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>AMS samples were analyzed at Lawrence Livermore National Laboratory under the auspices of the DOE contract DE-AC52-07NA27344. We gratefully acknowledge the Susan and Gerry Knapp Family Fund. The work reported here does not represent the views or opinions of the Department of Veterans Affairs or the United States Government.</p></ack><ref-list><title>References</title><ref id="pone.0146256.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>X</given-names></name>, <name><surname>Okuda</surname><given-names>T</given-names></name>, <name><surname>Holzer</surname><given-names>A</given-names></name>, <name><surname>Howell</surname><given-names>SB</given-names></name>. <article-title>The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae</article-title>. <source>Molecular pharmacology</source>. <year>2002</year>;<volume>62</volume>(<issue>5</issue>):<fpage>1154</fpage>&#x02013;<lpage>9</lpage>. .<?supplied-pmid 12391279?><pub-id pub-id-type="pmid">12391279</pub-id></mixed-citation></ref><ref id="pone.0146256.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Lippard</surname><given-names>SJ</given-names></name>. <article-title>Cellular processing of platinum anticancer drugs</article-title>. <source>Nature reviews Drug discovery</source>. <year>2005</year>;<volume>4</volume>(<issue>4</issue>):<fpage>307</fpage>&#x02013;<lpage>20</lpage>. Epub 2005/03/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd1691">10.1038/nrd1691</ext-link></comment> .<?supplied-pmid 15789122?><pub-id pub-id-type="pmid">15789122</pub-id></mixed-citation></ref><ref id="pone.0146256.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Samimi</surname><given-names>G</given-names></name>, <name><surname>Katano</surname><given-names>K</given-names></name>, <name><surname>Holzer</surname><given-names>AK</given-names></name>, <name><surname>Safaei</surname><given-names>R</given-names></name>, <name><surname>Howell</surname><given-names>SB</given-names></name>. <article-title>Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B</article-title>. <source>Molecular pharmacology</source>. <year>2004</year>;<volume>66</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/mol.66.1.25">10.1124/mol.66.1.25</ext-link></comment> .<?supplied-pmid 15213293?><pub-id pub-id-type="pmid">15213293</pub-id></mixed-citation></ref><ref id="pone.0146256.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Yonezawa</surname><given-names>A</given-names></name>, <name><surname>Masuda</surname><given-names>S</given-names></name>, <name><surname>Yokoo</surname><given-names>S</given-names></name>, <name><surname>Katsura</surname><given-names>T</given-names></name>, <name><surname>Inui</surname><given-names>K</given-names></name>. <article-title>Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)</article-title>. <source>The Journal of pharmacology and experimental therapeutics</source>. <year>2006</year>;<volume>319</volume>(<issue>2</issue>):<fpage>879</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1124/jpet.106.110346">10.1124/jpet.106.110346</ext-link></comment> .<?supplied-pmid 16914559?><pub-id pub-id-type="pmid">16914559</pub-id></mixed-citation></ref><ref id="pone.0146256.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>SW</given-names></name>, <name><surname>Swiggard</surname><given-names>PA</given-names></name>, <name><surname>Handel</surname><given-names>LM</given-names></name>, <name><surname>Brennan</surname><given-names>JM</given-names></name>, <name><surname>Godwin</surname><given-names>AK</given-names></name>, <name><surname>Ozols</surname><given-names>RF</given-names></name>, <etal>et al</etal><article-title>Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells</article-title>. <source>Cancer Res</source>. <year>1994</year>;<volume>54</volume>(<issue>22</issue>):<fpage>5911</fpage>&#x02013;<lpage>6</lpage>. .<?supplied-pmid 7954422?><pub-id pub-id-type="pmid">7954422</pub-id></mixed-citation></ref><ref id="pone.0146256.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>SW</given-names></name>, <name><surname>Laub</surname><given-names>PB</given-names></name>, <name><surname>Beesley</surname><given-names>JS</given-names></name>, <name><surname>Ozols</surname><given-names>RF</given-names></name>, <name><surname>Hamilton</surname><given-names>TC</given-names></name>. <article-title>Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>5</issue>):<fpage>850</fpage>&#x02013;<lpage>6</lpage>. .<?supplied-pmid 9041185?><pub-id pub-id-type="pmid">9041185</pub-id></mixed-citation></ref><ref id="pone.0146256.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Kool</surname><given-names>M</given-names></name>, <name><surname>de Haas</surname><given-names>M</given-names></name>, <name><surname>Scheffer</surname><given-names>GL</given-names></name>, <name><surname>Scheper</surname><given-names>RJ</given-names></name>, <name><surname>van Eijk</surname><given-names>MJ</given-names></name>, <name><surname>Juijn</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>16</issue>):<fpage>3537</fpage>&#x02013;<lpage>47</lpage>. .<?supplied-pmid 9270026?><pub-id pub-id-type="pmid">9270026</pub-id></mixed-citation></ref><ref id="pone.0146256.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>DP</given-names><suffix>Jr</suffix></name>, <name><surname>Klein</surname><given-names>E</given-names></name>, <name><surname>Fair</surname><given-names>WR</given-names></name>, <name><surname>Chaganti</surname><given-names>RS</given-names></name>. <article-title>Metallothionein gene expression in bladder cancer exposed to cisplatin</article-title>. <source>Mod Pathol</source>. <year>1993</year>;<volume>6</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>5</lpage>. .<?supplied-pmid 8426855?><pub-id pub-id-type="pmid">8426855</pub-id></mixed-citation></ref><ref id="pone.0146256.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Plasencia</surname><given-names>C</given-names></name>, <name><surname>Martinez-Balibrea</surname><given-names>E</given-names></name>, <name><surname>Martinez-Cardus</surname><given-names>A</given-names></name>, <name><surname>Quinn</surname><given-names>DI</given-names></name>, <name><surname>Abad</surname><given-names>A</given-names></name>, <name><surname>Neamati</surname><given-names>N</given-names></name>. <article-title>Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells</article-title>. <source>Int J Oncol</source>. <year>2006</year>;<volume>29</volume>(<issue>1</issue>):<fpage>225</fpage>&#x02013;<lpage>35</lpage>. .<?supplied-pmid 16773204?><pub-id pub-id-type="pmid">16773204</pub-id></mixed-citation></ref><ref id="pone.0146256.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Hector</surname><given-names>S</given-names></name>, <name><surname>Nava</surname><given-names>ME</given-names></name>, <name><surname>Clark</surname><given-names>K</given-names></name>, <name><surname>Murphy</surname><given-names>M</given-names></name>, <name><surname>Pendyala</surname><given-names>L</given-names></name>. <article-title>Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10</article-title>. <source>Cancer letters</source>. <year>2007</year>;<volume>245</volume>(<issue>1&#x02013;2</issue>):<fpage>195</fpage>&#x02013;<lpage>204</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.canlet.2006.01.007">10.1016/j.canlet.2006.01.007</ext-link></comment> .<?supplied-pmid 16516375?><pub-id pub-id-type="pmid">16516375</pub-id></mixed-citation></ref><ref id="pone.0146256.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Jamieson</surname><given-names>ER</given-names></name>, <name><surname>Lippard</surname><given-names>SJ</given-names></name>. <article-title>Structure, Recognition, and Processing of Cisplatin-DNA Adducts</article-title>. <source>Chemical reviews</source>. <year>1999</year>;<volume>99</volume>(<issue>9</issue>):<fpage>2467</fpage>&#x02013;<lpage>98</lpage>. Epub 2001/12/26. .<?supplied-pmid 11749487?><pub-id pub-id-type="pmid">11749487</pub-id></mixed-citation></ref><ref id="pone.0146256.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Chaney</surname><given-names>SG</given-names></name>, <name><surname>Campbell</surname><given-names>SL</given-names></name>, <name><surname>Temple</surname><given-names>B</given-names></name>, <name><surname>Bassett</surname><given-names>E</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>, <name><surname>Faldu</surname><given-names>M</given-names></name>. <article-title>Protein interactions with platinum-DNA adducts: from structure to function</article-title>. <source>J Inorg Biochem</source>. <year>2004</year>;<volume>98</volume>(<issue>10</issue>):<fpage>1551</fpage>&#x02013;<lpage>9</lpage>. .<?supplied-pmid 15458816?><pub-id pub-id-type="pmid">15458816</pub-id></mixed-citation></ref><ref id="pone.0146256.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Kelland</surname><given-names>LR</given-names></name>. <article-title>New platinum antitumor complexes</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>1993</year>;<volume>15</volume>(<issue>3</issue>):<fpage>191</fpage>&#x02013;<lpage>219</lpage>. .<?supplied-pmid 8142057?><pub-id pub-id-type="pmid">8142057</pub-id></mixed-citation></ref><ref id="pone.0146256.ref014"><label>14</label><mixed-citation publication-type="book"><name><surname>JJ</surname><given-names>R</given-names></name>, <name><surname>RJ</surname><given-names>K</given-names></name>, <name><surname>FF</surname></name>. <source>DNA as the target for cytotoxic and antitumor action of platinum coordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin</source>. <name><surname>DCH</surname><given-names>M</given-names></name>, <name><surname>TF</surname><given-names>S</given-names></name>, editors: <publisher-loc>Oxford</publisher-loc>; <year>1986</year>.</mixed-citation></ref><ref id="pone.0146256.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Mauldin</surname><given-names>SK</given-names></name>, <name><surname>Gibbons</surname><given-names>G</given-names></name>, <name><surname>Wyrick</surname><given-names>SD</given-names></name>, <name><surname>Chaney</surname><given-names>SG</given-names></name>. <article-title>Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line</article-title>. <source>Cancer Res</source>. <year>1988</year>;<volume>48</volume>(<issue>18</issue>):<fpage>5136</fpage>&#x02013;<lpage>44</lpage>. .<?supplied-pmid 3409241?><pub-id pub-id-type="pmid">3409241</pub-id></mixed-citation></ref><ref id="pone.0146256.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Di Francesco</surname><given-names>AM</given-names></name>, <name><surname>Ruggiero</surname><given-names>A</given-names></name>, <name><surname>Riccardi</surname><given-names>R</given-names></name>. <article-title>Cellular and molecular aspects of drugs of the future: oxaliplatin</article-title>. <source>Cellular and molecular life sciences: CMLS</source>. <year>2002</year>;<volume>59</volume>(<issue>11</issue>):<fpage>1914</fpage>&#x02013;<lpage>27</lpage>. .<?supplied-pmid 12530522?><pub-id pub-id-type="pmid">12530522</pub-id></mixed-citation></ref><ref id="pone.0146256.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>MA</given-names></name>, <name><surname>Lockwood</surname><given-names>GF</given-names></name>, <name><surname>Greenslade</surname><given-names>D</given-names></name>, <name><surname>Brienza</surname><given-names>S</given-names></name>, <name><surname>Bayssas</surname><given-names>M</given-names></name>, <name><surname>Gamelin</surname><given-names>E</given-names></name>. <article-title>Clinical pharmacokinetics of oxaliplatin: a critical review</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>;<volume>6</volume>(<issue>4</issue>):<fpage>1205</fpage>&#x02013;<lpage>18</lpage>. .<?supplied-pmid 10778943?><pub-id pub-id-type="pmid">10778943</pub-id></mixed-citation></ref><ref id="pone.0146256.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Woynarowski</surname><given-names>JM</given-names></name>, <name><surname>Faivre</surname><given-names>S</given-names></name>, <name><surname>Herzig</surname><given-names>MC</given-names></name>, <name><surname>Arnett</surname><given-names>B</given-names></name>, <name><surname>Chapman</surname><given-names>WG</given-names></name>, <name><surname>Trevino</surname><given-names>AV</given-names></name>, <etal>et al</etal>
<article-title>Oxaliplatin-induced damage of cellular DNA</article-title>. <source>Molecular pharmacology</source>. <year>2000</year>;<volume>58</volume>(<issue>5</issue>):<fpage>920</fpage>&#x02013;<lpage>7</lpage>. .<?supplied-pmid 11040038?><pub-id pub-id-type="pmid">11040038</pub-id></mixed-citation></ref><ref id="pone.0146256.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Rixe</surname><given-names>O</given-names></name>, <name><surname>Ortuzar</surname><given-names>W</given-names></name>, <name><surname>Alvarez</surname><given-names>M</given-names></name>, <name><surname>Parker</surname><given-names>R</given-names></name>, <name><surname>Reed</surname><given-names>E</given-names></name>, <name><surname>Paull</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel</article-title>. <source>Biochemical pharmacology</source>. <year>1996</year>;<volume>52</volume>(<issue>12</issue>):<fpage>1855</fpage>&#x02013;<lpage>65</lpage>. Epub 1996/12/24. .<?supplied-pmid 8951344?><pub-id pub-id-type="pmid">8951344</pub-id></mixed-citation></ref><ref id="pone.0146256.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Gibbons</surname><given-names>GR</given-names></name>, <name><surname>Page</surname><given-names>JD</given-names></name>, <name><surname>Mauldin</surname><given-names>SK</given-names></name>, <name><surname>Husain</surname><given-names>I</given-names></name>, <name><surname>Chaney</surname><given-names>SG</given-names></name>. <article-title>Role of carrier ligand in platinum resistance in L1210 cells</article-title>. <source>Cancer Res</source>. <year>1990</year>;<volume>50</volume>(<issue>20</issue>):<fpage>6497</fpage>&#x02013;<lpage>501</lpage>. .<?supplied-pmid 2208108?><pub-id pub-id-type="pmid">2208108</pub-id></mixed-citation></ref><ref id="pone.0146256.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Saris</surname><given-names>CP</given-names></name>, <name><surname>van de Vaart</surname><given-names>PJ</given-names></name>, <name><surname>Rietbroek</surname><given-names>RC</given-names></name>, <name><surname>Blommaert</surname><given-names>FA</given-names></name>. <article-title>In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells</article-title>. <source>Carcinogenesis</source>. <year>1996</year>;<volume>17</volume>(<issue>12</issue>):<fpage>2763</fpage>&#x02013;<lpage>9</lpage>. Epub 1996/12/01. .<?supplied-pmid 9006117?><pub-id pub-id-type="pmid">9006117</pub-id></mixed-citation></ref><ref id="pone.0146256.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Ali-Osman</surname><given-names>F</given-names></name>, <name><surname>Berger</surname><given-names>MS</given-names></name>, <name><surname>Rairkar</surname><given-names>A</given-names></name>, <name><surname>Stein</surname><given-names>DE</given-names></name>. <article-title>Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy</article-title>. <source>J Cell Biochem</source>. <year>1994</year>;<volume>54</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>9</lpage>. .<?supplied-pmid 8126081?><pub-id pub-id-type="pmid">8126081</pub-id></mixed-citation></ref><ref id="pone.0146256.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Chao</surname><given-names>CC</given-names></name>, <name><surname>Lee</surname><given-names>YL</given-names></name>, <name><surname>Cheng</surname><given-names>PW</given-names></name>, <name><surname>Lin-Chao</surname><given-names>S</given-names></name>. <article-title>Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II)</article-title>. <source>Cancer Res</source>. <year>1991</year>;<volume>51</volume>(<issue>2</issue>):<fpage>601</fpage>&#x02013;<lpage>5</lpage>. .<?supplied-pmid 1898714?><pub-id pub-id-type="pmid">1898714</pub-id></mixed-citation></ref><ref id="pone.0146256.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Lai</surname><given-names>GM</given-names></name>, <name><surname>Ozols</surname><given-names>RF</given-names></name>, <name><surname>Smyth</surname><given-names>JF</given-names></name>, <name><surname>Young</surname><given-names>RC</given-names></name>, <name><surname>Hamilton</surname><given-names>TC</given-names></name>. <article-title>Enhanced DNA repair and resistance to cisplatin in human ovarian cancer</article-title>. <source>Biochem Pharmacol</source>. <year>1988</year>;<volume>37</volume>(<issue>24</issue>):<fpage>4597</fpage>&#x02013;<lpage>600</lpage>. .<?supplied-pmid 3144285?><pub-id pub-id-type="pmid">3144285</pub-id></mixed-citation></ref><ref id="pone.0146256.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Hill</surname><given-names>BT</given-names></name>, <name><surname>Shellard</surname><given-names>SA</given-names></name>, <name><surname>Hosking</surname><given-names>LK</given-names></name>, <name><surname>Fichtinger-Schepman</surname><given-names>AM</given-names></name>, <name><surname>Bedford</surname><given-names>P</given-names></name>. <article-title>Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation</article-title>. <source>International journal of radiation oncology, biology, physics</source>. <year>1990</year>;<volume>19</volume>(<issue>1</issue>):<fpage>75</fpage>&#x02013;<lpage>83</lpage>. Epub 1990/07/01. .<?supplied-pmid 2380098?><pub-id pub-id-type="pmid">2380098</pub-id></mixed-citation></ref><ref id="pone.0146256.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Zdraveski</surname><given-names>ZZ</given-names></name>, <name><surname>Mello</surname><given-names>JA</given-names></name>, <name><surname>Farinelli</surname><given-names>CK</given-names></name>, <name><surname>Essigmann</surname><given-names>JM</given-names></name>, <name><surname>Marinus</surname><given-names>MG</given-names></name>. <article-title>MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA</article-title>. <source>The Journal of biological chemistry</source>. <year>2002</year>;<volume>277</volume>(<issue>2</issue>):<fpage>1255</fpage>&#x02013;<lpage>60</lpage>. Epub 2001/11/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M105382200">10.1074/jbc.M105382200</ext-link></comment> .<?supplied-pmid 11705991?><pub-id pub-id-type="pmid">11705991</pub-id></mixed-citation></ref><ref id="pone.0146256.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Vaisman</surname><given-names>A</given-names></name>, <name><surname>Varchenko</surname><given-names>M</given-names></name>, <name><surname>Umar</surname><given-names>A</given-names></name>, <name><surname>Kunkel</surname><given-names>TA</given-names></name>, <name><surname>Risinger</surname><given-names>JI</given-names></name>, <name><surname>Barrett</surname><given-names>JC</given-names></name>, <etal>et al</etal>
<article-title>The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts</article-title>. <source>Cancer research</source>. <year>1998</year>;<volume>58</volume>(<issue>16</issue>):<fpage>3579</fpage>&#x02013;<lpage>85</lpage>. Epub 1998/08/29. .<?supplied-pmid 9721864?><pub-id pub-id-type="pmid">9721864</pub-id></mixed-citation></ref><ref id="pone.0146256.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Goel</surname><given-names>A</given-names></name>, <name><surname>Nagasaka</surname><given-names>T</given-names></name>, <name><surname>Arnold</surname><given-names>CN</given-names></name>, <name><surname>Inoue</surname><given-names>T</given-names></name>, <name><surname>Hamilton</surname><given-names>C</given-names></name>, <name><surname>Niedzwiecki</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer</article-title>. <source>Gastroenterology</source>. <year>2007</year>;<volume>132</volume>(<issue>1</issue>):<fpage>127</fpage>&#x02013;<lpage>38</lpage>. Epub 2006/11/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.gastro.2006.09.018">10.1053/j.gastro.2006.09.018</ext-link></comment> .<?supplied-pmid 17087942?><pub-id pub-id-type="pmid">17087942</pub-id></mixed-citation></ref><ref id="pone.0146256.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Weisenberger</surname><given-names>DJ</given-names></name>, <name><surname>Siegmund</surname><given-names>KD</given-names></name>, <name><surname>Campan</surname><given-names>M</given-names></name>, <name><surname>Young</surname><given-names>J</given-names></name>, <name><surname>Long</surname><given-names>TI</given-names></name>, <name><surname>Faasse</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer</article-title>. <source>Nature genetics</source>. <year>2006</year>;<volume>38</volume>(<issue>7</issue>):<fpage>787</fpage>&#x02013;<lpage>93</lpage>. Epub 2006/06/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng1834">10.1038/ng1834</ext-link></comment> .<?supplied-pmid 16804544?><pub-id pub-id-type="pmid">16804544</pub-id></mixed-citation></ref><ref id="pone.0146256.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Matsuoka</surname><given-names>S</given-names></name>, <name><surname>Ballif</surname><given-names>BA</given-names></name>, <name><surname>Smogorzewska</surname><given-names>A</given-names></name>, <name><surname>McDonald</surname><given-names>ER</given-names><suffix>3rd</suffix></name>, <name><surname>Hurov</surname><given-names>KE</given-names></name>, <name><surname>Luo</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage</article-title>. <source>Science</source>. <year>2007</year>;<volume>316</volume>(<issue>5828</issue>):<fpage>1160</fpage>&#x02013;<lpage>6</lpage>. Epub 2007/05/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1140321">10.1126/science.1140321</ext-link></comment> .<?supplied-pmid 17525332?><pub-id pub-id-type="pmid">17525332</pub-id></mixed-citation></ref><ref id="pone.0146256.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Grossman</surname><given-names>HB</given-names></name>, <name><surname>Natale</surname><given-names>RB</given-names></name>, <name><surname>Tangen</surname><given-names>CM</given-names></name>, <name><surname>Speights</surname><given-names>VO</given-names></name>, <name><surname>Vogelzang</surname><given-names>NJ</given-names></name>, <name><surname>Trump</surname><given-names>DL</given-names></name>, <etal>et al</etal>
<article-title>Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer</article-title>. <source>The New England journal of medicine</source>. <year>2003</year>;<volume>349</volume>(<issue>9</issue>):<fpage>859</fpage>&#x02013;<lpage>66</lpage>. Epub 2003/08/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa022148">10.1056/NEJMoa022148</ext-link></comment> .<?supplied-pmid 12944571?><pub-id pub-id-type="pmid">12944571</pub-id></mixed-citation></ref><ref id="pone.0146256.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>von der Maase</surname><given-names>H</given-names></name>, <name><surname>Hansen</surname><given-names>SW</given-names></name>, <name><surname>Roberts</surname><given-names>JT</given-names></name>, <name><surname>Dogliotti</surname><given-names>L</given-names></name>, <name><surname>Oliver</surname><given-names>T</given-names></name>, <name><surname>Moore</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2000</year>;<volume>18</volume>(<issue>17</issue>):<fpage>3068</fpage>&#x02013;<lpage>77</lpage>. Epub 2000/09/23. .<?supplied-pmid 11001674?><pub-id pub-id-type="pmid">11001674</pub-id></mixed-citation></ref><ref id="pone.0146256.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Ehrsson</surname><given-names>H</given-names></name>, <name><surname>Wallin</surname><given-names>I</given-names></name>, <name><surname>Yachnin</surname><given-names>J</given-names></name>. <article-title>Pharmacokinetics of oxaliplatin in humans</article-title>. <source>Medical oncology</source>. <year>2002</year>;<volume>19</volume>(<issue>4</issue>):<fpage>261</fpage>&#x02013;<lpage>5</lpage>. Epub 2003/01/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1385/MO:19:4:261">10.1385/MO:19:4:261</ext-link></comment> .<?supplied-pmid 12512920?><pub-id pub-id-type="pmid">12512920</pub-id></mixed-citation></ref><ref id="pone.0146256.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Mosmann</surname><given-names>T</given-names></name>. <article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title>. <source>J Immunol Methods</source>. <year>1983</year>;<volume>65</volume>(<issue>1&#x02013;2</issue>):<fpage>55</fpage>&#x02013;<lpage>63</lpage>. .<?supplied-pmid 6606682?><pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="pone.0146256.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Fujiwara</surname><given-names>K</given-names></name>, <name><surname>Yamauchi</surname><given-names>H</given-names></name>, <name><surname>Suzuki</surname><given-names>S</given-names></name>, <name><surname>Ishikawa</surname><given-names>H</given-names></name>, <name><surname>Tanaka</surname><given-names>Y</given-names></name>, <name><surname>Fujiwara</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2001</year>;<volume>47</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>6</lpage>. .<?supplied-pmid 11221957?><pub-id pub-id-type="pmid">11221957</pub-id></mixed-citation></ref><ref id="pone.0146256.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>H</given-names></name>, <name><surname>Thatcher</surname><given-names>N</given-names></name>, <name><surname>Baer</surname><given-names>J</given-names></name>, <name><surname>Zaki</surname><given-names>A</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>McAucliffe</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>1983</year>;<volume>11</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>7</lpage>. .<?supplied-pmid 6349844?><pub-id pub-id-type="pmid">6349844</pub-id></mixed-citation></ref><ref id="pone.0146256.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Ognibene</surname><given-names>TJ</given-names></name>, <name><surname>Bench</surname><given-names>G</given-names></name>, <name><surname>Vogel</surname><given-names>JS</given-names></name>, <name><surname>Peaslee</surname><given-names>GF</given-names></name>, <name><surname>Murov</surname><given-names>S</given-names></name>. <article-title>A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry</article-title>. <source>Analytical chemistry</source>. <year>2003</year>;<volume>75</volume>(<issue>9</issue>):<fpage>2192</fpage>&#x02013;<lpage>6</lpage>. Epub 2003/05/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/ac026334j">10.1021/ac026334j</ext-link></comment> .<?supplied-pmid 12720362?><pub-id pub-id-type="pmid">12720362</pub-id></mixed-citation></ref><ref id="pone.0146256.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Hendrickson</surname><given-names>DG</given-names></name>, <name><surname>Sauvageau</surname><given-names>M</given-names></name>, <name><surname>Goff</surname><given-names>L</given-names></name>, <name><surname>Rinn</surname><given-names>JL</given-names></name>, <name><surname>Pachter</surname><given-names>L</given-names></name>. <article-title>Differential analysis of gene regulation at transcript resolution with RNA-seq</article-title>. <source>Nature biotechnology</source>. <year>2013</year>;<volume>31</volume>(<issue>1</issue>):<fpage>46</fpage>&#x02013;<lpage>53</lpage>. Epub 2012/12/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.2450">10.1038/nbt.2450</ext-link></comment> ; PubMed Central PMCID: PMC3869392.<?supplied-pmid 23222703?><pub-id pub-id-type="pmid">23222703</pub-id></mixed-citation></ref><ref id="pone.0146256.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Roberts</surname><given-names>A</given-names></name>, <name><surname>Goff</surname><given-names>L</given-names></name>, <name><surname>Pertea</surname><given-names>G</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <name><surname>Kelley</surname><given-names>DR</given-names></name>, <etal>et al</etal>
<article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title>. <source>Nature protocols</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>562</fpage>&#x02013;<lpage>78</lpage>. Epub 2012/03/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2012.016">10.1038/nprot.2012.016</ext-link></comment> ; PubMed Central PMCID: PMC3334321.<?supplied-pmid 22383036?><pub-id pub-id-type="pmid">22383036</pub-id></mixed-citation></ref><ref id="pone.0146256.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Griffith</surname><given-names>OW</given-names></name>, <name><surname>Meister</surname><given-names>A</given-names></name>. <article-title>Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)</article-title>. <source>J Biol Chem</source>. <year>1979</year>;<volume>254</volume>(<issue>16</issue>):<fpage>7558</fpage>&#x02013;<lpage>60</lpage>. <?supplied-pmid 38242?><pub-id pub-id-type="pmid">38242</pub-id></mixed-citation></ref><ref id="pone.0146256.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>K</given-names></name>, <name><surname>Dingley</surname><given-names>KH</given-names></name>, <name><surname>Turteltaub</surname><given-names>KW</given-names></name>. <article-title>Accelerator mass spectrometry for biomedical research</article-title>. <source>Methods in enzymology</source>. <year>2005</year>;<volume>402</volume>:<fpage>423</fpage>&#x02013;<lpage>43</lpage>. Epub 2006/01/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0076-6879(05)02014-8">10.1016/S0076-6879(05)02014-8</ext-link></comment> .<?supplied-pmid 16401518?><pub-id pub-id-type="pmid">16401518</pub-id></mixed-citation></ref><ref id="pone.0146256.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Cimino</surname><given-names>GD</given-names></name>, <name><surname>Pan</surname><given-names>CX</given-names></name>, <name><surname>Henderson</surname><given-names>PT</given-names></name>. <article-title>Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer</article-title>. <source>Bioanalysis</source>. <year>2013</year>;<volume>5</volume>(<issue>3</issue>):<fpage>369</fpage>&#x02013;<lpage>91</lpage>. Epub 2013/02/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4155/bio.12.325">10.4155/bio.12.325</ext-link></comment> ; PubMed Central PMCID: PMC3644565.<?supplied-pmid 23394702?><pub-id pub-id-type="pmid">23394702</pub-id></mixed-citation></ref><ref id="pone.0146256.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Dallas</surname><given-names>NA</given-names></name>, <name><surname>Xia</surname><given-names>L</given-names></name>, <name><surname>Fan</surname><given-names>F</given-names></name>, <name><surname>Gray</surname><given-names>MJ</given-names></name>, <name><surname>Gaur</surname><given-names>P</given-names></name>, <name><surname>van Buren</surname><given-names>G</given-names></name>, 2nd, <etal>et al</etal>
<article-title>Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition</article-title>. <source>Cancer research</source>. <year>2009</year>;<volume>69</volume>(<issue>5</issue>):<fpage>1951</fpage>&#x02013;<lpage>7</lpage>. Epub 2009/02/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-08-2023">10.1158/0008-5472.CAN-08-2023</ext-link></comment> ; PubMed Central PMCID: PMC3198868.<?supplied-pmid 19244128?><pub-id pub-id-type="pmid">19244128</pub-id></mixed-citation></ref><ref id="pone.0146256.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Virag</surname><given-names>P</given-names></name>, <name><surname>Brie</surname><given-names>I</given-names></name>, <name><surname>Fischer-Fodor</surname><given-names>E</given-names></name>, <name><surname>Perde-Schrepler</surname><given-names>M</given-names></name>, <name><surname>Tatomir</surname><given-names>C</given-names></name>, <name><surname>Balacescu</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance</article-title>. <source>Cell biochemistry and function</source>. <year>2011</year>;<volume>29</volume>(<issue>5</issue>):<fpage>351</fpage>&#x02013;<lpage>5</lpage>. Epub 2011/04/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cbf.1754">10.1002/cbf.1754</ext-link></comment> .<?supplied-pmid 21491469?><pub-id pub-id-type="pmid">21491469</pub-id></mixed-citation></ref><ref id="pone.0146256.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Virag</surname><given-names>P</given-names></name>, <name><surname>Fischer-Fodor</surname><given-names>E</given-names></name>, <name><surname>Perde-Schrepler</surname><given-names>M</given-names></name>, <name><surname>Brie</surname><given-names>I</given-names></name>, <name><surname>Tatomir</surname><given-names>C</given-names></name>, <name><surname>Balacescu</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins</article-title>. <source>BMC genomics</source>. <year>2013</year>;<volume>14</volume>:<fpage>480</fpage> Epub 2013/07/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-14-480">10.1186/1471-2164-14-480</ext-link></comment> ; PubMed Central PMCID: PMC3776436.<?supplied-pmid 23865481?><pub-id pub-id-type="pmid">23865481</pub-id></mixed-citation></ref><ref id="pone.0146256.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Virag</surname><given-names>P</given-names></name>, <name><surname>Perde-Schrepler</surname><given-names>M</given-names></name>, <name><surname>Fischer-Fodor</surname><given-names>E</given-names></name>, <name><surname>Tatomir</surname><given-names>C</given-names></name>, <name><surname>Dorneanu</surname><given-names>SA</given-names></name>, <name><surname>Cernea</surname><given-names>VI</given-names></name>, <etal>et al</etal>
<article-title>Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines</article-title>. <source>Anti-cancer drugs</source>. <year>2012</year>;<volume>23</volume>(<issue>10</issue>):<fpage>1032</fpage>&#x02013;<lpage>8</lpage>. Epub 2012/05/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CAD.0b013e328355076f">10.1097/CAD.0b013e328355076f</ext-link></comment> .<?supplied-pmid 22614106?><pub-id pub-id-type="pmid">22614106</pub-id></mixed-citation></ref><ref id="pone.0146256.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Silva</surname><given-names>MJ</given-names></name>, <name><surname>Costa</surname><given-names>P</given-names></name>, <name><surname>Dias</surname><given-names>A</given-names></name>, <name><surname>Valente</surname><given-names>M</given-names></name>, <name><surname>Louro</surname><given-names>H</given-names></name>, <name><surname>Boavida</surname><given-names>MG</given-names></name>. <article-title>Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells</article-title>. <source>Environmental and molecular mutagenesis</source>. <year>2005</year>;<volume>46</volume>(<issue>2</issue>):<fpage>104</fpage>&#x02013;<lpage>15</lpage>. Epub 2005/05/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/em.20138">10.1002/em.20138</ext-link></comment> .<?supplied-pmid 15887215?><pub-id pub-id-type="pmid">15887215</pub-id></mixed-citation></ref><ref id="pone.0146256.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Sweeney</surname><given-names>CJ</given-names></name>, <name><surname>Roth</surname><given-names>BJ</given-names></name>, <name><surname>Kabbinavar</surname><given-names>FF</given-names></name>, <name><surname>Vaughn</surname><given-names>DJ</given-names></name>, <name><surname>Arning</surname><given-names>M</given-names></name>, <name><surname>Curiel</surname><given-names>RE</given-names></name>, <etal>et al</etal>
<article-title>Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2006</year>;<volume>24</volume>(<issue>21</issue>):<fpage>3451</fpage>&#x02013;<lpage>7</lpage>. Epub 2006/07/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2005.03.6699">10.1200/JCO.2005.03.6699</ext-link></comment> .<?supplied-pmid 16849761?><pub-id pub-id-type="pmid">16849761</pub-id></mixed-citation></ref><ref id="pone.0146256.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Vaughn</surname><given-names>DJ</given-names></name>, <name><surname>Broome</surname><given-names>CM</given-names></name>, <name><surname>Hussain</surname><given-names>M</given-names></name>, <name><surname>Gutheil</surname><given-names>JC</given-names></name>, <name><surname>Markowitz</surname><given-names>AB</given-names></name>. <article-title>Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2002</year>;<volume>20</volume>(<issue>4</issue>):<fpage>937</fpage>&#x02013;<lpage>40</lpage>. Epub 2002/02/15. .<?supplied-pmid 11844814?><pub-id pub-id-type="pmid">11844814</pub-id></mixed-citation></ref><ref id="pone.0146256.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Henderson</surname><given-names>PT</given-names></name>, <name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>He</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Malfatti</surname><given-names>M</given-names></name>, <name><surname>Gandara</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance</article-title>. <source>International journal of cancer Journal international du cancer</source>. <year>2011</year>;<volume>129</volume>(<issue>6</issue>):<fpage>1425</fpage>&#x02013;<lpage>34</lpage>. Epub 2010/12/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.25814">10.1002/ijc.25814</ext-link></comment> ; PubMed Central PMCID: PMC3145006.<?supplied-pmid 21128223?><pub-id pub-id-type="pmid">21128223</pub-id></mixed-citation></ref><ref id="pone.0146256.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Ferry</surname><given-names>KV</given-names></name>, <name><surname>Hamilton</surname><given-names>TC</given-names></name>, <name><surname>Johnson</surname><given-names>SW</given-names></name>. <article-title>Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF</article-title>. <source>Biochemical pharmacology</source>. <year>2000</year>;<volume>60</volume>(<issue>9</issue>):<fpage>1305</fpage>&#x02013;<lpage>13</lpage>. Epub 2000/09/29. .<?supplied-pmid 11008124?><pub-id pub-id-type="pmid">11008124</pub-id></mixed-citation></ref><ref id="pone.0146256.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Weaver</surname><given-names>DA</given-names></name>, <name><surname>Crawford</surname><given-names>EL</given-names></name>, <name><surname>Warner</surname><given-names>KA</given-names></name>, <name><surname>Elkhairi</surname><given-names>F</given-names></name>, <name><surname>Khuder</surname><given-names>SA</given-names></name>, <name><surname>Willey</surname><given-names>JC</given-names></name>. <article-title>ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines</article-title>. <source>Molecular cancer</source>. <year>2005</year>;<volume>4</volume>(<issue>1</issue>):<fpage>18</fpage> Epub 2005/05/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1476-4598-4-18">10.1186/1476-4598-4-18</ext-link></comment> ; PubMed Central PMCID: PMC1156938.<?supplied-pmid 15882455?><pub-id pub-id-type="pmid">15882455</pub-id></mixed-citation></ref><ref id="pone.0146256.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Kuhnl</surname><given-names>A</given-names></name>, <name><surname>Gokbuget</surname><given-names>N</given-names></name>, <name><surname>Stroux</surname><given-names>A</given-names></name>, <name><surname>Burmeister</surname><given-names>T</given-names></name>, <name><surname>Neumann</surname><given-names>M</given-names></name>, <name><surname>Heesch</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>18</issue>):<fpage>3737</fpage>&#x02013;<lpage>44</lpage>. Epub 2010/01/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2009-09-241943">10.1182/blood-2009-09-241943</ext-link></comment> .<?supplied-pmid 20065290?><pub-id pub-id-type="pmid">20065290</pub-id></mixed-citation></ref><ref id="pone.0146256.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Matsunaga</surname><given-names>T</given-names></name>, <name><surname>Hojo</surname><given-names>A</given-names></name>, <name><surname>Yamane</surname><given-names>Y</given-names></name>, <name><surname>Endo</surname><given-names>S</given-names></name>, <name><surname>El-Kabbani</surname><given-names>O</given-names></name>, <name><surname>Hara</surname><given-names>A</given-names></name>. <article-title>Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers</article-title>. <source>Chemico-biological interactions</source>. <year>2013</year>;<volume>202</volume>(<issue>1&#x02013;3</issue>):<fpage>234</fpage>&#x02013;<lpage>42</lpage>. Epub 2012/11/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cbi.2012.09.024">10.1016/j.cbi.2012.09.024</ext-link></comment> .<?supplied-pmid 23165153?><pub-id pub-id-type="pmid">23165153</pub-id></mixed-citation></ref><ref id="pone.0146256.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Shirato</surname><given-names>A</given-names></name>, <name><surname>Kikugawa</surname><given-names>T</given-names></name>, <name><surname>Miura</surname><given-names>N</given-names></name>, <name><surname>Tanji</surname><given-names>N</given-names></name>, <name><surname>Takemori</surname><given-names>N</given-names></name>, <name><surname>Higashiyama</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells</article-title>. <source>Oncology letters</source>. <year>2014</year>;<volume>7</volume>(<issue>3</issue>):<fpage>674</fpage>&#x02013;<lpage>8</lpage>. Epub 2014/02/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/ol.2013.1768">10.3892/ol.2013.1768</ext-link></comment> ; PubMed Central PMCID: PMC3919892.<?supplied-pmid 24527071?><pub-id pub-id-type="pmid">24527071</pub-id></mixed-citation></ref><ref id="pone.0146256.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Matsunaga</surname><given-names>T</given-names></name>, <name><surname>Yamaguchi</surname><given-names>A</given-names></name>, <name><surname>Morikawa</surname><given-names>Y</given-names></name>, <name><surname>Kezuka</surname><given-names>C</given-names></name>, <name><surname>Takazawa</surname><given-names>H</given-names></name>, <name><surname>Endo</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells</article-title>. <source>Anti-cancer drugs</source>. <year>2014</year>;<volume>25</volume>(<issue>8</issue>):<fpage>868</fpage>&#x02013;<lpage>77</lpage>. Epub 2014/04/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CAD.0000000000000112">10.1097/CAD.0000000000000112</ext-link></comment> .<?supplied-pmid 24743520?><pub-id pub-id-type="pmid">24743520</pub-id></mixed-citation></ref><ref id="pone.0146256.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>YJ</given-names></name>, <name><surname>Yuan</surname><given-names>CC</given-names></name>, <name><surname>Chow</surname><given-names>KC</given-names></name>, <name><surname>Wang</surname><given-names>PH</given-names></name>, <name><surname>Lai</surname><given-names>CR</given-names></name>, <name><surname>Yen</surname><given-names>MS</given-names></name>, <etal>et al</etal>
<article-title>Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients</article-title>. <source>Gynecologic oncology</source>. <year>2005</year>;<volume>97</volume>(<issue>1</issue>):<fpage>110</fpage>&#x02013;<lpage>7</lpage>. Epub 2005/03/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ygyno.2004.12.031">10.1016/j.ygyno.2004.12.031</ext-link></comment> .<?supplied-pmid 15790446?><pub-id pub-id-type="pmid">15790446</pub-id></mixed-citation></ref><ref id="pone.0146256.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>HW</given-names></name>, <name><surname>Lin</surname><given-names>CP</given-names></name>, <name><surname>Chiu</surname><given-names>JH</given-names></name>, <name><surname>Chow</surname><given-names>KC</given-names></name>, <name><surname>Kuo</surname><given-names>KT</given-names></name>, <name><surname>Lin</surname><given-names>CS</given-names></name>, <etal>et al</etal>
<article-title>Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin</article-title>. <source>International journal of cancer Journal international du cancer</source>. <year>2007</year>;<volume>120</volume>(<issue>9</issue>):<fpage>2019</fpage>&#x02013;<lpage>27</lpage>. Epub 2007/02/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.22402">10.1002/ijc.22402</ext-link></comment> .<?supplied-pmid 17266043?><pub-id pub-id-type="pmid">17266043</pub-id></mixed-citation></ref><ref id="pone.0146256.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Menendez</surname><given-names>JA</given-names></name>, <name><surname>Mehmi</surname><given-names>I</given-names></name>, <name><surname>Griggs</surname><given-names>DW</given-names></name>, <name><surname>Lupu</surname><given-names>R</given-names></name>. <article-title>The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives</article-title>. <source>Endocrine-related cancer</source>. <year>2003</year>;<volume>10</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>52</lpage>. Epub 2003/06/07. .<?supplied-pmid 12790776?><pub-id pub-id-type="pmid">12790776</pub-id></mixed-citation></ref><ref id="pone.0146256.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>XY</given-names></name>, <name><surname>Wang</surname><given-names>XQ</given-names></name>, <name><surname>Qu</surname><given-names>JG</given-names></name>, <name><surname>Zhang</surname><given-names>JX</given-names></name>. <article-title>Effect of Cyr61 on the chemoresistance of pancreatic cancer</article-title>. <source>Journal of Jiangsu University (Medicine Edition)</source>. <year>2011</year>;<volume>21</volume>(<issue>4</issue>):<fpage>308</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0146256.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Chien</surname><given-names>J</given-names></name>, <name><surname>Aletti</surname><given-names>G</given-names></name>, <name><surname>Baldi</surname><given-names>A</given-names></name>, <name><surname>Catalano</surname><given-names>V</given-names></name>, <name><surname>Muretto</surname><given-names>P</given-names></name>, <name><surname>Keeney</surname><given-names>GL</given-names></name>, <etal>et al</etal>
<article-title>Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity</article-title>. <source>The Journal of clinical investigation</source>. <year>2006</year>;<volume>116</volume>(<issue>7</issue>):<fpage>1994</fpage>&#x02013;<lpage>2004</lpage>. Epub 2006/06/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI27698">10.1172/JCI27698</ext-link></comment> ; PubMed Central PMCID: PMC1474818.<?supplied-pmid 16767218?><pub-id pub-id-type="pmid">16767218</pub-id></mixed-citation></ref><ref id="pone.0146256.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>Y</given-names></name>, <name><surname>Jiang</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Sun</surname><given-names>N</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Xie</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties</article-title>. <source>Journal of cellular biochemistry</source>. <year>2014</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1112</fpage>&#x02013;<lpage>21</lpage>. Epub 2013/12/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcb.24751">10.1002/jcb.24751</ext-link></comment> .<?supplied-pmid 24356998?><pub-id pub-id-type="pmid">24356998</pub-id></mixed-citation></ref><ref id="pone.0146256.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Khurana</surname><given-names>A</given-names></name>, <name><surname>Maguire</surname><given-names>JL</given-names></name>, <name><surname>Chien</surname><given-names>J</given-names></name>, <name><surname>Shridhar</surname><given-names>V</given-names></name>. <article-title>HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation</article-title>. <source>International journal of cancer Journal international du cancer</source>. <year>2012</year>;<volume>130</volume>(<issue>5</issue>):<fpage>1029</fpage>&#x02013;<lpage>35</lpage>. Epub 2011/03/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.26044">10.1002/ijc.26044</ext-link></comment> ; PubMed Central PMCID: PMC3206182.<?supplied-pmid 21387310?><pub-id pub-id-type="pmid">21387310</pub-id></mixed-citation></ref><ref id="pone.0146256.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Catalano</surname><given-names>V</given-names></name>, <name><surname>Mellone</surname><given-names>P</given-names></name>, <name><surname>d'Avino</surname><given-names>A</given-names></name>, <name><surname>Shridhar</surname><given-names>V</given-names></name>, <name><surname>Staccioli</surname><given-names>MP</given-names></name>, <name><surname>Graziano</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer</article-title>. <source>Histopathology</source>. <year>2011</year>;<volume>58</volume>(<issue>5</issue>):<fpage>669</fpage>&#x02013;<lpage>78</lpage>. Epub 2011/03/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2559.2011.03818.x">10.1111/j.1365-2559.2011.03818.x</ext-link></comment> .<?supplied-pmid 21447133?><pub-id pub-id-type="pmid">21447133</pub-id></mixed-citation></ref><ref id="pone.0146256.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>HM</given-names></name>, <name><surname>Wang</surname><given-names>TC</given-names></name>. <article-title>Mechanism of cisplatin resistance in human urothelial carcinoma cells</article-title>. <source>Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association</source>. <year>2012</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1226</fpage>&#x02013;<lpage>37</lpage>. Epub 2012/02/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.fct.2012.01.040">10.1016/j.fct.2012.01.040</ext-link></comment> .<?supplied-pmid 22326969?><pub-id pub-id-type="pmid">22326969</pub-id></mixed-citation></ref><ref id="pone.0146256.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Trigueros-Motos</surname><given-names>L</given-names></name>, <name><surname>Perez-Torras</surname><given-names>S</given-names></name>, <name><surname>Casado</surname><given-names>FJ</given-names></name>, <name><surname>Molina-Arcas</surname><given-names>M</given-names></name>, <name><surname>Pastor-Anglada</surname><given-names>M</given-names></name>. <article-title>Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs</article-title>. <source>BMC cancer</source>. <year>2012</year>;<volume>12</volume>:<fpage>434</fpage> Epub 2012/09/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-12-434">10.1186/1471-2407-12-434</ext-link></comment> ; PubMed Central PMCID: PMC3517434.<?supplied-pmid 23017148?><pub-id pub-id-type="pmid">23017148</pub-id></mixed-citation></ref><ref id="pone.0146256.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Tamashiro</surname><given-names>DA</given-names></name>, <name><surname>Alarcon</surname><given-names>VB</given-names></name>, <name><surname>Marikawa</surname><given-names>Y</given-names></name>. <article-title>Nkx1-2 is a transcriptional repressor and is essential for the activation of Brachyury in P19 mouse embryonal carcinoma cell</article-title>. <source>Differentiation; research in biological diversity</source>. <year>2012</year>;<volume>83</volume>(<issue>5</issue>):<fpage>282</fpage>&#x02013;<lpage>92</lpage>. Epub 2012/04/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.diff.2012.02.010">10.1016/j.diff.2012.02.010</ext-link></comment> ; PubMed Central PMCID: PMC3590073.<?supplied-pmid 22475651?><pub-id pub-id-type="pmid">22475651</pub-id></mixed-citation></ref><ref id="pone.0146256.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Menon</surname><given-names>T</given-names></name>, <name><surname>Yates</surname><given-names>JA</given-names></name>, <name><surname>Bochar</surname><given-names>DA</given-names></name>. <article-title>Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8</article-title>. <source>Molecular endocrinology</source>. <year>2010</year>;<volume>24</volume>(<issue>6</issue>):<fpage>1165</fpage>&#x02013;<lpage>74</lpage>. Epub 2010/03/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1210/me.2009-0421">10.1210/me.2009-0421</ext-link></comment> ; PubMed Central PMCID: PMC2875808.<?supplied-pmid 20308527?><pub-id pub-id-type="pmid">20308527</pub-id></mixed-citation></ref><ref id="pone.0146256.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Leung</surname><given-names>CS</given-names></name>, <name><surname>Yeung</surname><given-names>TL</given-names></name>, <name><surname>Yip</surname><given-names>KP</given-names></name>, <name><surname>Pradeep</surname><given-names>S</given-names></name>, <name><surname>Balasubramanian</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential</article-title>. <source>Nature communications</source>. <year>2014</year>;<volume>5</volume>:<fpage>5092</fpage> Epub 2014/10/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms6092">10.1038/ncomms6092</ext-link></comment> ; PubMed Central PMCID: PMC4185407.<?supplied-pmid 25277212?><pub-id pub-id-type="pmid">25277212</pub-id></mixed-citation></ref><ref id="pone.0146256.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Cheetham</surname><given-names>SW</given-names></name>, <name><surname>Gruhl</surname><given-names>F</given-names></name>, <name><surname>Mattick</surname><given-names>JS</given-names></name>, <name><surname>Dinger</surname><given-names>ME</given-names></name>. <article-title>Long noncoding RNAs and the genetics of cancer</article-title>. <source>British journal of cancer</source>. <year>2013</year>;<volume>108</volume>(<issue>12</issue>):<fpage>2419</fpage>&#x02013;<lpage>25</lpage>. Epub 2013/05/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.2013.233">10.1038/bjc.2013.233</ext-link></comment> ; PubMed Central PMCID: PMC3694235.<?supplied-pmid 23660942?><pub-id pub-id-type="pmid">23660942</pub-id></mixed-citation></ref></ref-list></back></article>